

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Anticipated Classification of This Application: Class
Subclass

Prior Application: Examiner B. ROBINSON Art Unit 1612
THE COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20231

Sir:

Transmitted herewith for filing is a continuation under 37 C.F.R. 1.53(b), of pending prior Application Serial Number 09/348,711, filed on July 7, 1999 of Richard A. Mueller and Daniel P. Getman entitled **RETROVIRAL PROTEASE INHIBITORS**.

[X] Enclosed is a copy of the prior application, including the Oath of Declaration as originally filed July 7, 1999. I hereby verify that the attached papers are a true copy of said prior application as originally filed on July 7, 1999.

[] Cancel in this application, original Claims ___ of the prior application before calculating the filing fee. (At least one original, independent claim must be retained for filing purposes)

[X] Amend the specification by inserting before the first line the sentence: -- This is a continuation of pending prior Application Serial Number 09/348,711, filed on July 7, 1999. --

[] A preliminary amendment is enclosed.

[X] The filing fee is calculated below:

Basic Filing Fee [37 CFR 1.16(a)]				\$690.00
Additional Filing Fee [37 CFR 1.16(b), (c)]				
Claims	No. Filed	No. Extra	Rate	
Independent	8 - 3 =	5	X \$78.00 =	\$390.00
Total	99 - 20 =	70	X \$18.00 =	\$1260.00
TOTAL FEE:				\$2340.00

[X] A triplicate copy of this transmittal paper is enclosed.

[X] Please charge the above calculated total fee to my Deposit Account No. 19-1025.

[X] The Commissioner is hereby authorized and requested to charge any fees in addition to the above as well as all future fees set forth in 37 CFR 1.16 and 1.17 which may be required during the entire pendency of this Application, and credit any overcharges to Deposit Account No. 19-1025 [37 CFR 1.25(b)].

**NOTE: THIS AUTHORIZATION DOES NOT INCLUDE
FEES REQUIRED UNDER 37 CFR 1.18**

☐ Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. ANOTHER DUPLICATE COPY OF THIS SHEET IS ENCLOSED FOR FILING IN THE PRIOR APPLICATION FILE.

☐ New formal drawings are enclosed.

☐ Priority of Application Serial No. _____, filed on _____ in _____ (country) is claimed under 35 U.S.C. 119.

☐ The certified copy of the priority application has been filed in prior Application Serial No. _____, filed _____.

☒ The prior application is assigned of record to G.D. Searle & Co., P.O. Box 5110, Chicago, Illinois 60680.

☒ The Power of Attorney in the prior application is to J. Timothy Keane, Registration No. 27,808.

☒ The power appears in the original papers in the prior application.

☐ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.


☐ Enclosed is an Associate Power of Attorney from J. Timothy Keane to _____.

☒ Address all future communications to:

Pharmacia Corporation
Corporate Patent Department
P.O. Box 5110
Chicago, Illinois 60680

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 26 July 2000


J. Timothy Keane
Attorney for Applicants
Registration No. 27,808
314-694-9090 (St. Louis)

Pharmacia Corporation
Corporate Patent Department
P.O. Box 5110
Chicago, Illinois 60680

RETROVIRAL PROTEASE INHIBITORS

5

BACKGROUND OF THE INVENTION1. FIELD OF INVENTION

10 The present invention relates to retroviral protease inhibitors and, more particularly relates to novel compounds and a composition and method for inhibiting retroviral proteases. This invention, in particular, relates to N-heterocyclic moiety containing hydroxyethylamine protease inhibitor compounds, a
15 composition and method for inhibiting retroviral proteases such as human immunodeficiency virus (HIV) protease and for treatment or prophylaxis of a retroviral infection, e.g., an HIV infection. The subject invention also relates to processes for making
20 such compounds as well as to intermediates useful in such processes.

2. RELATED ART

25 During the replication cycle of retroviruses, gag and gag-poll gene products are translated as proteins. These proteins are subsequently processed by a virally encoded protease (or proteinase) to yield viral enzymes and structural proteins of the virus core. Most
30 commonly, the gag precursor proteins are processed into the core proteins and the poll precursor proteins are processed into the viral enzymes, e.g., reverse

transcriptase and retroviral protease. It has been shown that correct processing of the precursor proteins by the retroviral protease is necessary for assembly of infectious virions. For example, it has been shown that frameshift mutations in the protease region of the poll gene of HIV prevents processing of the gag precursor protein. It has also been shown through site-directed mutagenesis of an aspartic acid residue in the HIV protease that processing of the gag precursor protein is prevented. Thus, attempts have been made to inhibit viral replication by inhibiting the action of retroviral proteases.

Retroviral protease inhibition typically involves a transition state mimetic whereby the retroviral protease is exposed to a mimetic compound which binds (typically in a reversible manner) to the enzyme in competition with the gag and gag-poll proteins to thereby inhibit replication of structural proteins and, more importantly, the retroviral protease itself. In this manner, retroviral proteases can be effectively inhibited.

Several classes of mimetic compounds are known to be useful as inhibitors of the proteolytic enzyme renin. See, for example, U.S. 4,599,198; G.B. 2,184,730; G.B. 2,209,752; EP O 264 795; G.B. 2,200,115 and U.S. SIR H725. Of these, G.B. 2,200,115; G.B. 2,209,752; EP O 264,795; U.S. SIR H725; and U.S. 4,599,198 disclose urea containing hydroxyethylamine renin inhibitors.

However, it is known that, although renin and HIV proteases are both classified as aspartyl proteases, compounds which are effective renin inhibitors generally cannot be predicted to be effective HIV protease inhibitors.

Several classes of mimetic compounds have been proposed, particularly for inhibition of proteases, such as for inhibition of HIV protease. Such mimetics include hydroxyethylamine isosteres and reduced amide isosteres. See, for example, EP O 346 847; EP O 342,541; Roberts et al, "Rational Design of Peptide Based Proteinase Inhibitors, "Science, 248, 358 (1990); and Erickson et al, "Design, Activity, and 2.8A Crystal Structure of a C₂ Symmetric Inhibitor Complexed to HIV-1 Protease," Science, 249, 527 (1990). EP O 346 847 and US 5,648,364 disclose certain N-heterocyclic moiety-containing hydroxyethylamine protease inhibitor compounds, but do not suggest or disclose those of the present invention. WO 95/09843, WO 96/28464, US 5,484,926, US 5,705,500, US 5,756,533, US 5,776,971 and Kaldor, Stephen W., "A systematic Study of P₁-P₃ Spanning Sidechains for the Inhibition of HIV-1 Protease", Bioorganic and Medicinal Chemistry Letters, 5, 715-720 (1995) disclose arylthiol containing hydroxyethylamine isosteres incorporated into HIV-protease inhibitors but do not suggest or disclose the compounds of the present invention.

While it has been suggested that no improvement in the in vitro or ex vivo potency of hydroxyethylamine based inhibitors of HIV-protease containing a P₂ asparagine can be made (Science, Roberts et al.), this is not the case.

Improvements over P₂ asparagine containing inhibitors are made. The moieties reported herein are expected to permit certain allowances over the aforementioned reference including proteolytic stability, duration of action in vivo and pharmacokinetic profile.


BRIEF DESCRIPTION OF THE INVENTION

The present invention is directed to virus inhibiting compounds and compositions. More particularly, the present invention is directed to retroviral protease inhibiting compounds and compositions, to a method of inhibiting retroviral proteases, to processes for preparing the compounds and to intermediates useful in such processes. The subject compounds are characterized as N-heterocyclic moiety containing hydroxyethylamine inhibitor compounds.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

In accordance with the present invention, there are provided several novel retroviral protease inhibiting compounds or a pharmaceutically acceptable salt, prodrug or ester thereof.

A preferred class of retroviral inhibitor compounds of the present invention are those represented by the formula:



10

(Formula I)

15

or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein:

20

25

30

R represents hydrogen, alkoxycarbonyl, aryloxy carbonylalkyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxy carbanoyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocycloxy carbonyl, heteroaralkoxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroarylcarbonyl, heteroaryloxy carbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aralkylaminoalkylcarbonyl, aminoalkanoyl, aminocarbonyl, aminocarbonylalkyl, alkylaminoalkylcarbonyl, and mono- and disubstituted aminocarbonyl and aminoalkanoyl radicals wherein the substituents are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl,

heterocycloalkyl, alkoxy carbonyl, arylalkyloxycarbonyl and heterocycloalkylalkyl radicals, or in the case of disubstituted aminoalkanoyl, said substituents along with the nitrogen atom to which they are attached form a heterocyclyl or heteroaryl radical;

R' represents radicals defined for R³, or R and R' together with the nitrogen to which they are attached form a heterocycloalkyl or heteroaryl radical;

10

R¹ represents hydrogen, -CH₂SO₂NH₂, -CO₂CH₃, -CH₂CO₂CH₃, -C(O)NH₂, -C(O)NHCH₃, -C(O)N(CH₃)₂, -CH₂C(O)NHCH₃, -CH₂C(O)N(CH₃)₂, alkyl, alkylthioalkyl, thiolalkyl and the corresponding sulfoxide and sulfone derivatives thereof, alkenyl, alkynyl, haloalkyl, alkoxyalkyl and cycloalkyl radicals and amino acid side chains selected from the group consisting of asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, leucine, isoleucine, allo-isoleucine, tert-leucine, alanine, phenylalanine, ornithine, histidine, norleucine, glutamine, valine, threonine, allo-threonine, serine, aspartic acid and beta-cyano alanine, side chains;

R² represents alkylthioalkyl, cycloalkylthioalkyl or arylthioalkyl radicals, which radicals are optionally substituted with a substituent selected from the group consisting of -NO₂, -OR¹⁵, -SR¹⁵, and halogen radicals, wherein R¹⁵ represents hydrogen and alkyl radicals;

30

R³ represents hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl,

cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, and heteroaralkyl radicals;


5 Y' represents O, S and NR³;

R⁴ and R⁵ together with the nitrogen atom to which they are bonded represent a N-heterocycle; and R⁵ represents hydrogen and alkyl radicals.

10

Another class of preferred inhibitor compounds of the present invention are those represented by the formula:

15



20

(Formula II)

or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein:

25

R' represents radicals defined for R³;

t represents either 0 or 1;

30

R¹ represents hydrogen, -CH₂SO₂NH₂, -CO₂CH₃, -CH₂CO₂CH₃, -C(=O)NH₂, -C(=O)NHCH₃, -C(=O)N(CH₃)₂, -CH₂C(=O)NHCH₃, -

CH₂C(=O)N(CH₃)₂, alkyl, alkylthioalkyl, thioalkyl and the corresponding sulfoxide and sulfone derivatives thereof, alkenyl, alkynyl, alkoxyalkyl, haloalkyl and cycloalkyl radicals and amino acid side chains selected from the group consisting of asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, leucine, isoleucine, allo-isoleucine, tert-leucine, alanine, phenylalanine, ornithine, histidine, norleucine, glutamine, valine, threonine, allo-threonine, serine, aspartic acid and beta-cyano alanine side chains;

R² represents alkylthioalkyl, cycloalkylthioalkyl or arylthioalkyl radicals, which radicals are optionally substituted with a substituent selected from the group consisting of -NO₂, -OR¹⁵, -SR¹⁵, and halogen radicals, wherein R¹⁵ represents hydrogen and alkyl radicals;

R³ represents hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, and heteroaralkyl radicals;

Y' represents O, S and NR³;


R⁴ and R⁵ together with the nitrogen atom to which they are bonded represent a N-heterocycle;

R⁶ represents hydrogen and alkyl radicals;

and R^{20} and R^{21} represent radicals as defined for R^1 .

Yet another preferred class of compounds of the present invention are those represented by the formula:

5



10

(Formula III)

or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein:

t represents either 0 or 1;

R^1 represents hydrogen, $-\text{CH}_2\text{SO}_2\text{NH}_2$, $-\text{CO}_2\text{CH}_3$, $-\text{CH}_2\text{CO}_2\text{CH}_3$, $-\text{C}(=\text{O})\text{NH}_2$, $-\text{C}(=\text{O})\text{NHCH}_3$, $-\text{C}(=\text{O})\text{N}(\text{CH}_3)_2$, $-\text{CH}_2\text{C}(=\text{O})\text{NHCH}_3$, $-\text{CH}_2\text{C}(=\text{O})\text{N}(\text{CH}_3)_2$, alkyl, thioalkyl, thioalkyl and the corresponding sulfoxide and sulfone derivatives thereof, alkenyl, alkynyl, alkoxyalkyl, haloalkyl and cycloalkyl radicals and amino acid side chains selected from the group consisting of asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, leucine, isoleucine, allo-isoleucine,

tert-leucine, alanine, phenylalanine, ornithine, histidine, norleucine, glutamine, valine, threonine, allo-threonine, serine, aspartic acid and beta-cyano alanine side chains;

5

R^2 represents alkylthioalkyl, cycloalkylthioalkyl, or arylthioalkyl radicals, which radicals are optionally substituted with a substituent selected from the group consisting of $-NO_2$, $-OR^{15}$, $-SR^{15}$, and halogen radicals, wherein R^{15} represents hydrogen and alkyl radicals;

10

R^3 represents hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, and heteroaralkyl radicals;

15

X' represent O, N and $C(R^{17})$ where R^{17} represents hydrogen and alkyl radicals;

20

Y' and Y'' independently represent O, S and NR^3 ;

R^4 and R^5 together with the nitrogen atom to which they are bonded represent a N-heterocycle;

25


R^6 represents hydrogen and alkyl radicals;

R^{30} , R^{31} and R^{32} independently represent radicals as defined for R^1 , or one of R^1 and R^{30} together with one of R^{31} and R^{32} and the carbon atoms to which they are attached form a cycloalkyl radical; and

30

R^{33} and R^{34} independently represent radicals as defined for R^3 , or R^{33} and R^{34} together with X' represent cycloalkyl, aryl, heterocyclyl and heteroaryl radicals, provided that when X' is O, R^{34} is absent.

Still another preferred class of compounds of the present invention are those represented by the formula:



(Formula IV)

or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein:

R represents hydrogen, alkoxycarbonyl, aryloxy carbonylalkyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxy carbanoyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocycloxy carbonyl, heteroaralkoxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroarylcarbonyl, heteroaryloxy carbonyl, heteroaroyl,

alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aralkylaminoalkylcarbonyl, aminoalkanoyl, aminocarbonyl, aminocarbonylalkyl, alkylaminoalkylcarbonyl, and mono-
5 and disubstituted aminocarbonyl and aminoalkanoyl radicals wherein the substituents are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or
10 in the case of disubstituted aminoalkanoyl, said substituents along with the nitrogen atom to which they are attached form a heterocyclyl or heteroaryl radical;

R' represents radicals defined for R', or R and R' together with the nitrogen to which they are attached form a heterocycloalkyl or heteroaryl radical;

n represents 1 or 2;

20 Rⁱ represents hydrogen, -CH₂SO₂NH₂, -CO₂CH₃, -CH₂CO₂CH₃, -C(0)NH₂, -C(0)NHCH₃, -C(0)N(CH₃)₂, -CH₂C(0)NHCH₃, -CH₂C(0)N(CH₃)₂, alkyl, alkylthioalkyl, thioalkyl and the corresponding sulfoxide and sulfone derivatives thereof, alkenyl, alkynyl, haloalkyl, alkoxyalkyl and cycloalkyl
25 radicals and amino acid side chains selected from the group consisting of asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, leucine, isoleucine, allo-isoleucine, tert-leucine, alanine, phenylalanine, ornithine,
30 histidine, norleucine, glutamine, valine, threonine, allo-threonine, serine, aspartic acid and beta-cyano alanine side chains;

$R^{1'}$ and $R^{1''}$ independently represent hydrogen and radicals as defined for R^3 ;

5 R^2 represents alkylthioalkyl, cycloalkylthioalkyl, or arylthioalkyl radicals, which radicals are optionally substituted with a substituent selected from the group consisting of $-\text{NO}_2$, $-\text{OR}^{15}$, $-\text{SR}^{15}$, and halogen radicals, wherein R^{15} represents hydrogen and alkyl radicals;

10

R^3 represents hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, and heteroaralkyl radicals;

15

Y' and Y'' independently represent O, S and NR^3 ;

20


R^4 and R^5 together with the nitrogen atom to which they are bonded represent a N-heterocycle;

R^6 and $R^{6'}$ independently represent hydrogen and alkyl radicals.

25

Another class of preferred inhibitor compounds of the present invention are those represented by the formula:

30



(Formula IIa)

5

or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein:

10 R' represents radicals defined for R³, or R and R' together with the nitrogen to which they are attached form a heterocycloalkyl or heteroaryl radical;

t represents either 0 or 1;

15

R¹ represents hydrogen, -CH₂SO₂NH₂, -CO₂CH₃, -CH₂CO₂CH₃, -C(0)NH₂, -C(0)NHCH₃, -C(0)N(CH₃)₂, -CH₂C(0)NHCH₃, -CH₂C(0)N(CH₃)₂, alkyl, alkylthioalkyl, thioalkyl and the corresponding sulfoxide and sulfone derivatives thereof, alkenyl, alkynyl and cycloalkyl radicals and amino acid side chains selected from the group consisting of asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, leucine, isoleucine, allo-isoleucine, tert-leucine, alanine, phenylalanine, ornithine, histidine, norleucine, glutamine, valine, threonine, allo-threonine, serine, aspartic acid and beta-cyano alanine side chains;

30

R² represents alkylthioalkyl, cycloalkylthioalkyl or arylthioalkyl radicals, which radicals are optionally substituted with a substituent selected from the group

consisting of $-\text{NO}_2$, $-\text{OR}^{15}$, $-\text{SR}^{15}$, and halogen radicals,
wherein R^{15} represents hydrogen and alkyl radicals;

5 R^3 represents hydrogen, alkyl, alkenyl, alkynyl,
haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl,
cycloalkylalkyl, heterocycloalkyl, heteroaryl,
heterocycloalkylalkyl, aryl, aralkyl, and heteroaralkyl
radicals;

10 Y' represents O, S and NR^3 ;

R^4 and R^5 together with the nitrogen atom to which they
are bonded represent a N-heterocycle;

15 R^6 represents hydrogen and alkyl radicals;

R^{33} and R^{34} independently represent radicals as defined
for R^3 , or R^{33} and R^{34} together with the nitrogen to which
they are attached form heterocyclyl and heteroaryl
20 radicals;

and R^{20} and R^{21} represent radicals as defined for R^1 .

As utilized herein, the term "alkyl", alone or in
25 combination, means a straight-chain or branched-chain
alkyl radical containing from 1 to about 10, preferably
from 1 to about 8, carbon atoms. Examples of such
radicals include methyl, ethyl, n-propyl, iso-propyl, n-
butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-
30 amyl, hexyl, octyl and the like. The term "thioalkyl"
means an alkyl radical having at least one sulfur atom,

wherein alkyl has the significance given above. An example of a thioalkyl is $-\text{C}(\text{CH}_3)_2\text{SCH}_3$. The corresponding sulfoxide and sulfone of this thioalkyl are $-\text{C}(\text{CH}_3)_2\text{S}(\text{O})\text{CH}_3$ and $(\text{CH}_3)_2\text{S}(\text{O})_2\text{CH}_3$, respectively. The term "alkenyl", alone or in combination, means a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing from 2 to about 18 carbon atoms preferably from 2 to about 8 carbon atoms. Examples of suitable alkenyl radicals include ethenyl, propenyl, allyl, 1,4-butadienyl and the like. The term "alkynyl", alone or in combination, means a straight-chain hydrocarbon radical having one or more triple bonds and containing from 2 to about 10 carbon atoms. Examples of alkynyl radicals include ethynyl, propynyl (propargyl), butynyl and the like. The term "alkoxy", alone or in combination, means an alkyl ether radical wherein the term alkyl is as defined above. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like. The term "cycloalkyl", alone or in combination, means an alkyl radical which contains from about 3 to about 8 carbon atoms and is cyclic. Examples of such cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. The term "cycloalkylalkyl" means an alkyl radical as defined above which is substituted by a cycloalkyl radical containing from about 3 to about 8, preferably from about 3 to about 6, carbon atoms. The term "aryl", alone or in combination, means a phenyl or naphthyl radical which optionally carries one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro and the like, such as phenyl (C_6H_5 -

), p-tolyl, 4-methoxyphenyl, 4-(tert-butoxy)phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 2-hydroxyphenyl, 4-nitrophenyl, 2-nitrophenyl, 1-naphthyl, 2-naphthyl, and the like. The term "aralkyl", alone or
5 in combination, means an alkyl radical as defined above in which one hydrogen atom is replaced by an aryl radical as defined above, such as benzyl, 2-phenylethyl and the like. The term "aralkoxy carbonyl", alone or in combination, means a radical of the formula $-C(=O)-O-$
10 aralkyl in which the term "aralkyl" has the significance given above. An example of an aralkoxycarbonyl radical is benzyloxycarbonyl. The term "aryloxy", alone or in combination, means a radical of the formula aryl-O- in which the term "aryl" has the significance given above.
15 The term "alkanoyl, alone or in combination, means an acyl radical derived from an alkanecarboxylic acid, examples of which include acetyl, propionyl, butyryl, valeryl, 4-methylvaleryl, and the like. The term "cycloalkylcarbonyl" means an acyl group derived from a
20 monocyclic or bridged cycloalkanecarboxylic acid such as cyclopropanecarbonyl, cyclohexanecarbonyl, adamantanecarbonyl, and the like, or from a benz-fused monocyclic cycloalknecarboxylic acid which is optionally substituted by, for example, alkanoylamino, such as
25 1,2,3,4-tetrahydro-2-naphthoyl, 2-acetamido-1,2,3,4-tetrahydro-2-naphthoyl. The term "aralkanoyl" means an acyl radical derived from an aryl-substituted alkanecarboxylic acid such as phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-
30 naphthyl)acetyl, 4-chlorohydrocinnamoyl, 4-aminohydrocinnamoyl, 4-methoxyhydrocinnamoyl, and the like. The term "aroyl" means an acyl radical derived

from an aromatic carboxylic acid. Examples of such radicals include aromatic carboxylic acids, an optionally substituted benzoic or naphthoic acid such as benzoyl, 4-chlorobenzoyl, 4-carboxybenzoyl, 4-
5 (benzyloxycarbonyl)benzoyl, 1-naphthoyl, 2-naphthoyl, 6-carboxy-2-naphthoyl, 6-(benzyloxycarbonyl)-2-naphthoyl, 3-benzyloxy-2-naphthoyl, 3-hydroxy-2-naphthoyl, 3-(benzyloxyformamido)-2-naphthoyl, and the like. The term "arylthioalkyl" (aryl-S-alkyl) means an aryl radical
10 as defined above attached to a sulfur atom that is attached to an alkyl radical as is defined above and with the preferred alkyl group being 1 to 3 carbon atoms inclusive and the preferred aryl ring being 6 to 10 carbon atoms inclusive and with the oxidation states of
15 sulfur including the sulfide (-S-), sulfoxide (-S(O)-), or sulfone (-S(O)₂-), with the preferred oxidation state of the sulfur being that of the sulfide (-S-). Most preferred is an aryl ring of 6 carbon atoms. The term "alkylthioalkyl" means an alkyl group of 1 to 6 carbon
20 atoms inclusive bonded to a sulfur atom which is bonded to an alkyl group of 1 to 3 carbon atoms inclusive. The heterocyclyl or heterocycloalkyl portion of a heterocyclylcarbonyl, heterocyclylloxycarbonyl, heterocyclylalkoxycarbonyl, or heterocyclylalkyl group
25 or the like is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic heterocycle which contains one or more hetero atoms selected from nitrogen, oxygen and sulphur, which is optionally substituted on one or more carbon atoms by halogen,
30 alkyl, alkoxy, oxo, and the like, and/or on a secondary nitrogen atom (i.e., -NH-) by alkyl, aralkoxycarbonyl, alkanoyl, phenyl or phenylalkyl or on a tertiary

nitrogen atom (i.e. =N-) by oxido and which is attached via a carbon atom. The heteroaryl portion of a heteroaroyl, heteroaryloxycarbonyl, or heteroaralkoxycarbonyl group or the like is an aromatic monocyclic, bicyclic, or tricyclic heterocycle which contains the hetero atoms and is optionally substituted as defined above with respect to the definition of heterocyclyl. Examples of such heterocyclyl and heteroaryl groups are pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, pyrrolyl, imidazolyl (e.g., imidazol-4-yl, 1-benzyloxycarbonylimidazol-4-yl, etc.), pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, furyl, tetrahydrofuryl, tetrahydrothienyl, thienyl, triazolyl, oxazolyl, thiazolyl, indolyl (e.g., 2-indolyl, etc.), quinolinyl (e.g., 2-quinolinyl, 3-quinolinyl, 1-oxido-2-quinolinyl, etc.), isoquinolinyl (e.g., 1-isoquinolinyl, 3-isoquinolinyl, etc.), tetrahydroquinolinyl (e.g., 1,2,3,4-tetrahydro-2-quinolinyl, etc.), 1,2,3,4-tetrahydroisoquinolinyl (e.g., 1,2,3,4-tetrahydro-1-oxo-isoquinolinyl, etc.), quinoxalinyl, beta-carbolinyl, 2-benzofurancarbonyl, 1-, 2-, 4- or 5-benzimidazolyl, benzofuryl, tetrahydrobenzofuryl and the like. Heteroaryl or heterocycl (heterocyclo, heterocycle) groups may be bonded through a heteroatom or carbon. The term "cycloalkylalkoxycarbonyl" means an acyl group derived from a cycloalkylalkoxycarboxylic acid of the formula cycloalkylalkyl-O-CO-OH wherein cycloalkylalkyl has the significance given above. The term "aryloxyalkanoyl" means an acyl radical of the formula aryl-O-alkanoyl wherein aryl and alkanoyl have the significance given above. The term

"heterocyclylalkanoyl" is an acyl radical derived from a heterocyclyl-substituted alkane carboxylic acid wherein heterocyclyl has the significance given above. The term "heterocyclyloxycarbonyl" means an acyl group derived from heterocyclyl-O-CO-OH wherein heterocyclyl is as defined above. The term "heterocyclylalkanoyl" means an acyl radical of the formula heterocyclyl-alkanoyl wherein heterocyclyl and alkanoyl have the significance given above. The term "heterocyclylalkoxycarbonyl" means an acyl radical derived from heterocyclyl-substituted alkane-O-CO-OH wherein heterocyclyl has the significance given above. The term "heteroaryloxycarbonyl" means an acyl radical derived from a carboxylic acid represented by heteroaryl-O-COOH wherein heteroaryl has the significance given above. The term "aminocarbonyl" alone or in combination, means an amino-substituted carbonyl (carbamoyl) group derived from an amino-substituted carboxylic acid (carbamic acid) N-(C=O)- wherein the amino group can be a primary, secondary or tertiary amino group containing substituents selected from hydrogen, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like. The term "aminoalkanoyl" means an acyl radical derived from an amino substituted alkanecarboxylic acid wherein the amino group can be a primary, secondary or tertiary amino group containing substituents selected from the group consisting of hydrogen, cycloalkyl, cycloalkylalkyl radicals and the like, examples of which include N-methylaminoacetyl, N-cyclopropylaminoacetyl, N-methoxyethylaminoacetyl, pyrrolidinyacetyl, N,N-dimethylaminoacetyl and N-benzylaminoacetyl. The term "halogen" means fluorine, chlorine, bromine or iodine.

The term haloalkyl means an alkyl group substituted with one or more halogen atoms on one or different carbons such as chloromethyl, chlorobromoethyl, trifluoromethyl, 2,2,2-trifluoromethylethylene and the like. The term

5 "leaving group" generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known and include carboxylates, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates, -OR


10 and -SR and the like. Preferred leaving groups are indicated herein where appropriate. The term hydroxypropylenediamine means hydroxyethylamine when applied to this class of protease inhibitors. The term "N-heterocyclic moiety" or N-heterocycle is a

15 heterocyclic radical or heterocycle bonded via its nitrogen or with a nitrogen atom radical bond site which may be a heterocycloalkyl or heteroaryl, wherein heterocycloalkyl and heteroaryl have the significance given above, with the addition that polycyclic


20 heteroaryl may be fully aromatic or partially aromatic, for example, a fused heterocycloalkylaryl and a fused heteroarylcycloalkyl, and the heterocycloalkyl and cycloalkyl may also be bridged. Preferably, the N-heterocyclic moiety has 5, 6 or 7 members when

25 monocyclic; 5, 6 or 7 members in a ring with 1, 2 or 3 members in a bridge when a bridged monocyclic; 11, 12 or 13 members when bicyclic; and 11 to 16 members when tricyclic. Examples of N-heterocyclic moieties include, but are not limited to, those represented by the


30 following formulae:




(A)




(B)




(C)




(D)




(E)




(F)



(G)



(H)




(J)

5 wherein:

R^9 represents hydrogen, alkyl, alkoxy carbonyl,
monoalkylcarbamoyl, monoaralkylcarbamoyl,
monoarylcarbamoyl or a group of the formula:

10



15

20 R^{10} and R^{11} each represents alkyl;

R^{12} represents hydrogen, hydroxy, alkoxy carbonylamino or
acylamino;

25 R^{13} represents hydrogen, alkyl, aryl, alkoxy carbonyl or
acyl;

m is 1, 2, 3, or 4;

30 p is 1 or 2; and

q is 0, 1 or 2.

The term prodrug means esters and amide derivatives of amines, acids, alcohols, thiols and the like that are able to be converted *in vitro* or *in vivo* by chemical or biochemical or metabolic processed into an active parent compound. A prodrug may or may not have intrinsic biological activity.

Procedures for preparing the compounds of Formulas I-IV are set forth below. It should be noted that the general procedures are shown as it relates to preparation of compounds having a specified stereochemistry, for example, wherein the stereochemistry about the hydroxyl group is designated as (R). However, such procedures are generally applicable to those compounds of opposite configuration, e.g., where the stereochemistry about the hydroxyl group is (S) or (RS). The terms (R) and (S) configuration are as defined by the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-30. The documents WO 95/09843, US 5,484,926, Kaldor, Stephen W., "A systematic Study of P₁-P₃ Spanning Sidechains for the Inhibition of HIV-1 Protease", Bioorganic and Medicinal Chemistry Letters, 5, 715-720 (1995), WO 96/28463, WO 96/28418, WO 96/28465, WO 96/22287, EP 0 346 847, US 5,648,364, WO 96/28464, US 5,521,219, US 5,463,104, US 5,843,946, US 5,756,533, US 5,776,971 and US 5,705,500 include supplementary or alternative methods for preparing intermediates or compounds useful or possibly useful for preparing compounds of this invention as required or desired by a


person of ordinary skill in the art which documents are incorporated herein by reference.

Preparation of Compounds of Formula I

5

The compounds of the present invention represented by formula I through IV above wherein R^2 is alkylthioalkyl or arylthioalkyl ($ArSCH_2-$) can be prepared utilizing the following general procedures as illustrated in some cases with compounds wherein R^2 is arylalkyl. An N-protected haloketone derivative of an amino acid having the formula:

15



20


25 (Formula VIII)

wherein P represents an amino protecting group, R^2 is as defined above and Z represents a chlorine, bromine or iodine atom, is reduced to the corresponding alcohol utilizing an appropriate reducing agent. Suitable amino protecting groups are well known in the art and include carbobenzoxy, butyryl, t-butoxycarbonyl, acetyl, benzoyl

30


and the like. Preferred amino protecting groups are carbobenzoxy and t-butoxycarbonyl. A preferred N-protected haloketone is a compound of Formula VIII wherein P is benzyloxycarbonyl (Z or CBZ), R² is phenylthioalkyl and the alkyl group has one carbon atom. A preferred reducing agent is sodium borohydride. The reduction reaction is conducted at a temperature of from -10°C to about 25°C, preferably at about 0°C, in a suitable solvent system such as, for example, tetrahydrofuran, and the like. The N-protected haloketones may be commercially available from Bachem, Inc., Torrance, California. Alternatively, the haloketones can be prepared by the procedure set forth in S. J. Pittkau, J. Prakt. Chem., 315, 1037 (1973), and subsequently N-protected utilizing procedures which are well known in the art.

The resulting alcohol is then reacted, preferably at room temperature, with a suitable base in a suitable solvent system to produce an N-protected amino epoxide of the formula:



wherein P and R² are as defined above. Suitable solvent systems for preparing the amino epoxide include methanol, ethanol, isopropanol, tetrahydrofuran, dioxane, and the like including mixtures thereof. Suitable bases for producing the epoxide from the reduced haloketone include potassium hydroxide, sodium hydroxide, potassium t-butoxide, DBU and the like. A preferred base is potassium hydroxide.

Alternatively, a protected amino epoxide can be prepared starting with an D, L or DL-amino acid (illustrated below with an L-aminoacid) which is reacted with a suitable amino- and carboxyl-protecting groups in a suitable solvent to produce an amino-protected L-amino acid ester of the formula:




30

wherein P¹ and P² independently represent hydrogen and amino-protecting groups as defined above with respect to

P, provided that P^1 and p^2 are not both hydrogen: P^1 represents hydrogen and a carboxy-protecting group, preferably one which is also an amino-protecting group as defined above with respect to P; and R^2 is as defined above.


The amino protected L-amino acid ester is then reduced, to the corresponding alcohol. For example, the amino-protected L-amino acid ester can be reduced with diisobutylaluminum hydride at -78°C in a suitable solvent such as toluene. The resulting alcohol is then converted, by way of a Swern Oxidation, to the corresponding aldehyde of the formula:



wherein P^1 , p^2 and R^2 are as defined above. Thus, a dichloromethane solution of the alcohol is added to a cooled (-75 to -68°C) solution of oxalyl chloride in dichloromethane and DMSO in dichloromethane and stirred for 35 minutes.

The aldehyde resulting from the Swern Oxidation is then reacted with a halomethyl lithium reagent, which reagent is generated in situ by reacting an alkyl lithium or

aryl lithium compound with a dihalomethane represented by the formula $X^1CH_2X^2$ wherein X^1 and x^2 independently represent I, Br or Cl. For example, a solution of the aldehyde and chloriodomethane in THF is cooled to -78°C and a solution of n-butyl lithium in hexane is added. The resulting product is a mixture of diastereomers of the corresponding amino-protected epoxides of the formulas:




The diastereomers can be separated by chromatography or, alternatively, once reacted in subsequent steps the distereomeric products can be separated.

The amino epoxide is then reacted, in a suitable solvent system, with an equivalent or more amount, of a heterocycle of the formula:




wherein R^4 and R^5 are as defined above. The reaction can be conducted over a wide range of temperatures, e.g.,


from about 60°C to about 120°C in an inert organic solvent, but is preferably, but not necessarily, conducted at a temperature at which the solvent begins to reflux. Suitable solvent systems include those wherein the solvent is an alcohol, such as methanol, ethanol, isopropanol, and the like, ethers such as tetrahydrofuran, dioxane and the like, toluene, N,N-dimethylformamide, dimethylsulfoxide, and mixtures thereof. A preferred solvent is isopropanol. Non-limiting examples of heterocycles corresponding to the formula HNR^4R^5 include those having the following formula:




(A)




(B)




(C)




(D)




(E)




(F)



(G)



(H)



(J)


wherein:

5

R^9 , R^{10} , R^{11} , R^{12} , R^{13} , m , p and q have the significance given above, and the like. The resulting product is a 3-(N-protected amino)-3-(R^2)-1-(NR^4R^5)-propan-2-ol

derivative (hereinafter referred to as an amino alcohol)
is an intermediate which contains the desired N-
heterocyclic moiety or intermediate thereof and can be
represented by the formula:

5




10

15

wherein p^1 , p^2 , R^2 , R^4 and R^5 are as described above.

Alternatively, the compounds of the present invention
represented by Formula I above can be prepared utilizing
the following general procedure. An N-protected
haloketone derivative of an amino acid having the
formula:

25



30


wherein P, P¹ and P² represent amino protecting groups, R² is as defined above, and Z represents a chlorine, bromine or iodine atom, is reacted, in a suitable inert organic solvent system, with an equal or greater
5 equivalent amount, of a desired amine of the formula:



10

wherein R⁴ and R⁵ are as defined above. The reaction yields a compound of the general formula:

15



20

(Formula V)

25


wherein p¹, p², R², R⁴ and R⁵ have the significance given earlier.

30

The reaction of the N-protected haloketone derivative of an amino acid, preferably one in which one of P¹ and/or p² represent benzyloxy carbonyl and one of P¹ and/or p² represent hydrogen, with the desired amine, a

heterocyclic compound of formula HNR^4R^5 , can be carried out in any known manner, for example, in an inert organic solvent such as halogenated aliphatic hydrocarbon (e.g. dichloromethane, N,N-dimethylformamide, tetrahydrofuran, isopropanol and ethanol) and in the presence of a base (e.g. a trialkylamine such as triethylamine and diisopropylethylamine, sodium bicarbonate, DBU and the like), conveniently at about room temperature.

The reduction of the aminoketone compound of Formula V results in a compound of the general formula:




(Formula VI)

wherein p^1 , p^2 , R^2 , R^4 and R^5 have the significance given earlier. The reduction of the aminoketone compound of Formula V to the N-heterocyclic moiety-containing derivative (Formula VI) can be carried out according to known methods for the reduction of a carbonyl group to a hydroxy group. Thus, for example, the reduction can be carried out using a complex metal hydride such as an alkali metal borohydride, especially sodium borohydride, in an appropriate organic solvent such as alkanol (e.g. methanol, ethanol, propanol, isopropanol etc.).

Conveniently, the reduction is carried out at about room temperature.

Following preparation of the N-heterocyclic moiety-
5 containing derivative, the amino protecting group P is,
or P¹ and P² are, removed under conditions which will not
affect the remaining portion of the molecule. These
methods are well known in the art and include acid
hydrolysis, hydrogenolysis and the like. A preferred
10 method involves removal of the protecting group, e.g.,
removal of a carbobenzoxy group, by hydrogenolysis
utilizing palladium on carbon in a suitable solvent
system such as an alcohol, acetic acid, and the like or
mixtures thereof. Where the protecting group is N,N-
15 dibenzyl, these groups may be removed by hydrogenolysis
utilizing palladium on carbon. Where the protecting
group is a t-butoxycarbonyl group, it can be removed
utilizing an inorganic or organic acid, e.g., HCl or
trifluoroacetic acid, in a suitable solvent system,
20 e.g., dioxane or methylene chloride. The resulting
product is the amine salt derivative. Following
neutralization of the salt, the amine is then reacted
with an amino acid or corresponding derivative thereof
represented by the formula (RR¹NCH(R¹)COOH) or
25 (RR¹N[CR^{1'}R^{1''}]CH(R¹)COOH) wherein R^{1'}, R^{1''} and R¹ are as
defined above and may be P and/or P¹ and/or P² to produce
the antiviral compounds of the present invention having
the formula:

30




Formula I

or

5

10



Formula IV

15

wherein P, R¹, R^{1'}, R^{1''}, R², R⁴ and R⁵ are as defined above. Preferred protecting groups in this instance are a benzyloxycarbonyl group or a t-butoxycarbonyl group.

20 Where the amine is reacted with a derivative of an amino acid and R^{1'} and R^{1''} are both hydrogen, so that the amino acid is a ,beta-amino acid, such, beta-amino acids can be prepared according to the procedure set forth in copending applications, U.S. Serial No. 07/836,163

25 Method of Preparing Optically Active, beta-Amino Acids; filed February 14, 1992; Docket No. 07-21(855)A) (a continuation of U.S.S.N. 07/706,508, now abandoned, which is a continuation of U.S.S.N. 07/345,808, now abandoned). Where one of R^{1'} and R^{1''} is hydrogen and R¹ is

30 hydrogen so that the amino acid is a homo-beta-amino acid, such homo-beta-amino acids can be prepared according to the procedure set forth in copending


application, U. S. Serial No. 07/853,561 (Method of
Preparing Optically Active Homo-beta-Amino Acids; filed;
Docket No. 07-21(722)A). The process thereof preserves
the chirality of the starting succinates. The method
5 thereof involves Curtis rearrangement of chiral 3-mono-
substituted succinates (succinic acid half ester) of
sufficient purity to exhibit optical activity. The
Curtis rearrangement is preferably effected by treating
a chiral 3-mono-substituted succinate with one
10 equivalent of diphenoxyphosphoryl azide (PhO)₂PON₃ and
triethylamine to form an acyl azide followed by heating
in an inert solvent, such as warm toluene, preferably at
about 80°C for about three hours to afford an isocyanate
derivative which is subsequently hydrolyzed to give
15 amines. The 3-mono-substituted succinates can be
prepared by a procedure analogous to that described in
U.S. 4,939,288, filed January 23, 1989, which is hereby
incorporated by reference. The alpha-amino acid
compounds are prepared using, for example, methods in US
20 5,483,946, or variations well know in the art. It
should be noted that compounds of this invention can be
prepared in stepwise as is shown by the example in
Scheme 1 and Scheme 2 herein below or via a convergent
synthesis where parts of the final product are made
25 separately and coupled in a final step to produce said
final product of this invention. The person skilled in
the art will select the appropriate process based on
compound to be made under particular conditions at that
particular time or location.

5

10

1. **Introduction**
 2. **Background**
 3. **Methodology**
 4. **Results**
 5. **Discussion**
 6. **Conclusion**
 7. **References**
 8. **Appendix**
 9. **Figure 1**
 10. **Figure 2**
 11. **Figure 3**
 12. **Figure 4**
 13. **Figure 5**
 14. **Figure 6**
 15. **Figure 7**
 16. **Figure 8**
 17. **Figure 9**
 18. **Figure 10**
 19. **Figure 11**
 20. **Figure 12**
 21. **Figure 13**
 22. **Figure 14**
 23. **Figure 15**
 24. **Figure 16**
 25. **Figure 17**
 26. **Figure 18**
 27. **Figure 19**
 28. **Figure 20**
 29. **Figure 21**
 30. **Figure 22**
 31. **Figure 23**
 32. **Figure 24**
 33. **Figure 25**
 34. **Figure 26**
 35. **Figure 27**
 36. **Figure 28**
 37. **Figure 29**
 38. **Figure 30**
 39. **Figure 31**
 40. **Figure 32**
 41. **Figure 33**
 42. **Figure 34**
 43. **Figure 35**
 44. **Figure 36**
 45. **Figure 37**
 46. **Figure 38**
 47. **Figure 39**
 48. **Figure 40**
 49. **Figure 41**
 50. **Figure 42**
 51. **Figure 43**
 52. **Figure 44**
 53. **Figure 45**
 54. **Figure 46**
 55. **Figure 47**
 56. **Figure 48**
 57. **Figure 49**
 58. **Figure 50**
 59. **Figure 51**
 60. **Figure 52**
 61. **Figure 53**
 62. **Figure 54**
 63. **Figure 55**
 64. **Figure 56**
 65. **Figure 57**
 66. **Figure 58**
 67. **Figure 59**
 68. **Figure 60**
 69. **Figure 61**
 70. **Figure 62**
 71. **Figure 63**
 72. **Figure 64**
 73. **Figure 65**
 74. **Figure 66**
 75. **Figure 67**
 76. **Figure 68**
 77. **Figure 69**
 78. **Figure 70**
 79. **Figure 71**
 80. **Figure 72**
 81. **Figure 73**
 82. **Figure 74**
 83. **Figure 75**
 84. **Figure 76**
 85. **Figure 77**
 86. **Figure 78**
 87. **Figure 79**
 88. **Figure 80**
 89. **Figure 81**
 90. **Figure 82**
 91. **Figure 83**
 92. **Figure 84**
 93. **Figure 85**
 94. **Figure 86**
 95. **Figure 87**
 96. **Figure 88**
 97. **Figure 89**
 98. **Figure 90**
 99. **Figure 91**
 100. **Figure 92**
 101. **Figure 93**
 102. **Figure 94**
 103. **Figure 95**
 104. **Figure 96**
 105. **Figure 97**
 106. **Figure 98**
 107. **Figure 99**
 108. **Figure 100**
 109. **Figure 101**
 110. **Figure 102**
 111. **Figure 103**
 112. **Figure 104**
 113. **Figure 105**
 114. **Figure 106**
 115. **Figure 107**
 116. **Figure 108**
 117. **Figure 109**
 118. **Figure 110**
 119. **Figure 111**
 120. **Figure 112**
 121. **Figure 113**
 122. **Figure 114**
 123. **Figure 115**
 124. **Figure 116**
 125. **Figure 117**
 126. **Figure 118**
 127. **Figure 119**
 128. **Figure 120**
 129. **Figure 121**
 130. **Figure 122**
 131. **Figure 123**
 132. **Figure 124**
 133. **Figure 125**
 134. **Figure 126**
 135. **Figure 127**
 136. **Figure 128**
 137. **Figure 129**
 138. **Figure 130**
 139. **Figure 131**
 140. **Figure 132**
 141. **Figure 133**
 142. **Figure 134**
 143. **Figure 135**
 144. **Figure 136**
 145. **Figure 137**
 146. **Figure 138**
 147. **Figure 139**
 148. **Figure 140**
 149. **Figure 141**
 150. **Figure 142**
 151. **Figure 143**
 152. **Figure 144**
 153. **Figure 145**
 154. **Figure 146**
 155. **Figure 147**
 156. **Figure 148**
 157. **Figure 149**
 158. **Figure 150**
 159. **Figure 151**
 160. **Figure 152**
 161. **Figure 153**
 162. **Figure 154**
 163. **Figure 155**
 164. **Figure 156**
 165. **Figure 157**
 166. **Figure 158**
 167. **Figure 159**
 168. **Figure 160**
 169. **Figure 161**
 170. **Figure 162**
 171. **Figure 163**
 172. **Figure 164**
 173. **Figure 165**
 174. **Figure 166**
 175. **Figure 167**
 176. **Figure 168**
 177. **Figure 169**
 178. **Figure 170**
 179. **Figure 171**
 180. **Figure 172**
 181. **Figure 173**
 182. **Figure 174**
 183. **Figure 175**
 184. **Figure 176**
 185. **Figure 177**
 186. **Figure 178**
 187. **Figure 179**
 188. **Figure 180**
 189. **Figure 181**
 190. **Figure 182**
 191. **Figure 183**
 192. **Figure 184**
 193. **Figure 185**
 194. **Figure 186**
 195. **Figure 187**
 196. **Figure 188**
 197. **Figure 189**
 198. **Figure 190**
 199. **Figure 191**
 200. **Figure 192**
 201. **Figure 193**
 202. **Figure 194**
 203. **Figure 195**
 204. **Figure 196**
 205. **Figure 197**
 206. **Figure 198**
 207. **Figure 199**
 208. **Figure 200**
 209. **Figure 201**
 210. **Figure 202**
 211. **Figure 203**
 212. **Figure 204**
 213. **Figure 205**
 214. **Figure 206**
 215. **Figure 207**
 216. **Figure 208**
 217. **Figure 209**



5



wherein R is as defined above and L is an appropriate
10 leaving group such as a halide. Examples of such
carboxylates include acetylchloride, phenoxyacetyl
chloride, benzoyl chloride, 2-naphthyloxycarbonyl
chloride and 2-benzofurancarbonyl chloride. A solution
of the free amine (or amine acetate salt) and about 1.0
15 equivalent of the carboxylate are mixed in an
appropriate solvent system and optionally treated with
up to five equivalents of a base such as, for example,
N-methylmorpholine, at about room temperature.
Appropriate solvent systems include tetrahydrofuran,
20 methylene chloride or N,N-dimethylformamide, and the
like, including mixtures thereof.

Alternatively, a sulfonyl-containing compound
represented by the formula:

25




30


wherein R is as defined above and L is an appropriate leaving group such as halide may be substituted for the aforementioned carboxylate.

5 Preparation of Compounds of Formula II

A mercaptan of the formula R'SH is reacted with a substituted methacrylate of the formula:




by way of a Michael Addition. The Michael Addition is conducted in a suitable solvent and in the presence of a suitable base, to produce the corresponding thiol derivative represented by the formula:



wherein R^1 and R^2 represent radicals defined above; R^{20}
and R^{21} represent hydrogen and radicals as defined for R^1 ;
and R^{22} represents alkyl, aryl or aralkyl, preferably R^{22}
5 is methyl, ethyl, t-butyl or benzyl. Suitable solvents
in which the Michael Addition can be conducted include
alcohols such as, for example, methanol, ethanol,
butanol and the like, as well as ethers, e.g., THF, and
acetonitrile, DMF, DMSO, and the like, including
10 mixtures thereof. Suitable bases include Group I metal
alkoxides such as, for example sodium methoxide, sodium
ethoxide, sodium butoxide and the like as well as Group
I metal hydrides, such as sodium hydride, including
mixtures thereof.

15 The thiol derivative is converted into the corresponding
sulfone of the formula:




25
30 by oxidizing the thiol derivative with a suitable
oxidation agent in a suitable solvent. Suitable
oxidation agents include, for example, hydrogen

5

10

[illegible]




10

utilizing a suitable base, e.g., lithium hydroxide,
15 sodium hydroxide, and the like, including mixtures
thereof, in a suitable solvent, such as, for example,
THF, acetonitrile, DMF, DMSO, methylene chloride and the
like, including mixtures thereof. When R^{22} is benzyl,
the free acid may be obtained by hydrogenolysis over
20 palladium on carbon.

The free acid is then coupled, utilizing, as described
above, procedures well known in the art, to the N-
heterocyclic moiety-containing derivative of an amino
25 alcohol which is described above for the preparation of
compounds of Formula I. The resulting product is a
compound represented by Formula II.


Alternatively, one can couple the N-heterocyclic moiety-
30 containing derivative to the commercially available
acid,



5

remove the thioacetyl group with a suitable base, such as hydroxide, or an amine, or ammonia, and then react the resulting thiol with an alkylating agent, such as an alkyl halide, tosylate or mesylate to afford compounds at the following structure:

10




15

20


The sulfur can then be oxidized to the corresponding sulfone using suitable oxidizing agents, as described above, to afford the desired compounds of the following structure:

25



5

10 Alternatively, to prepare compounds of Formula II, a substituted methacrylate of the formula:




15

20

25 wherein L represents a leaving group as previously defined, R³⁵ and R³⁶ represent hydrogen and radicals as defined for R¹; and R³⁷ represents alkyl, aralkyl, cycloalkyl and cycloalkylalkyl radicals, is reacted with a suitable sulfonating agent, such as, for example, a sulfinic acid represented by the formula R'SO₂M, wherein

30 R' represents radicals as defined above and M represents a metal adapted to form a salt of the acid, e.g.,


sodium, to produce the corresponding sulfone represented by the formula:



10

wherein R', R³⁵, R³⁶ and R³⁷ are as defined above. The sulfone is then hydrolyzed in the presence of a suitable base, such as lithium hydroxide, sodium hydroxide and the like, to the compound represented by the formula:

15




25

30 wherein R', R³⁵ and R³⁶ represent radicals as defined above. The resulting compound is then asymmetrically hydrogenated utilizing an asymmetric hydrogenation such

as, for example, a ruthenium-BINAP complex to produce the reduced product, substantially enriched in the more active isomer represented by the formula:

5



10

wherein R', R³⁵ and R³⁶ represent radicals as defined above. Where the more active isomer has the R-stereochemistry, a Ru(R-BINAP) asymmetric hydrogenation catalyst can be utilized. Conversely, where the more active isomer has the S-stereochemistry, a Ru(S-BINAP) catalyst can be utilized. Where both isomers are active, or where it is desired to have a mixture of the two diastereomers, a hydrogenation catalyst such as platinum, or palladium on carbon can be utilized to reduce the above compound. The reduced compound is then coupled to the N-heterocyclic moiety-containing derivative, as described above, to produce compounds of Formula II.


25

Alternatively, one can prepare the preferred 2(S)-methyl-3-(methanesulfonyl)propionic acid according to the scheme outlined below starting from commercially available D-(-)-S-benzoyl-beta-mercaptoisobutyric acid tert-butyl ester. Treatment of D-(-)-S-benzoyl-beta-mercaptoisobutyric acid tert-butyl ester with a


30

methanolic ammonia solution resulted in the formation of D-(-)-beta-mercaptoisobutyric acid tert-butyl ester and benzamide. The free mercaptan thus produced was freed from the benzamide by filtration and then further
5 purified by crystallization. Treatment of D-(-)-beta-mercaptoisobutyric acid tert-butyl ester with methyl iodide in the presence of a suitable base such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) results in the formation of the corresponding thioether S-methyl-D-(-)-
10 beta-mercaptoisobutyric acid tert-butylester in excellent yield. The thioether is then oxidized with a suitable oxidant such as sodium metaperborate in acetic acid to give the corresponding sulfone. Specifically, S-methyl-D-(-)-beta-mercaptoisobutyric acid tert-butyl
15 ester is treated with sodium perborate in acetic acid to produce 2(S)-methyl-3-(methylsulfonyl)propionic acid tert-butyl ester in excellent yield. The tert-butyl ester can then selectively removed by treatment with 4N hydrochloric acid in dioxane to produce 2(S)-methyl-3-(methylsulfonyl)propionic acid as a crystalline acid in
20 very good yield. It is envisioned that variations of the sulfur and carboxylate protecting groups would be acceptable for preparation of 2(S)-methyl-3-(methylsulfonyl)propionic acid and analogs.


5



10



15




20

25

30

Preparation of Compounds of Formula III


- 5 To produce compounds of Formula III, starting with a lactate of formula:



10

- wherein P' represents alkyl and aralkyl radicals, such
15 as, for example, ethyl, methyl, benzyl and the like.
The hydroxyl group of the lactate is protected as its
ketal by reaction in a suitable solvent system with
methyl isopropenyl ether (1,2-methoxypropene) in the
presence of a suitable acid. Suitable solvent systems
20 include methylene chloride, tetrahydrofuran and the like
as well as mixtures thereof. Suitable acids include
POCl₃, and the like. It should be noted that well-known
groups other than methyl isopropenyl ether can be
utilized to form the ketal. The ketal is then reduced
25 with diisobutylaluminum hydride (DIBAL) at -78°C to
produce the corresponding aldehyde which is then treated
with ethylidenetriphenylphosphorane (Wittig reaction) to
produce a compound represented by the formula:


30



5

The ketal protecting group is then removed utilizing procedures well-known in the art such as by mild acid hydrolysis. The resulting compound is then esterified with isobutyryl chloride to produce a compound of the formula:


10



15


This compound is then treated with lithium diisopropyl amide at -78°C followed by warming of the reaction mixture to room temperature to effect a Claisen rearrangement ([3,3]) to produce the corresponding acid represented by the formula:

25




30

Treatment of the acid with benzyl bromide (BnBr) in the presence of a tertiary amine base, e.g., DBU, produces the corresponding ester which is then cleaved oxidatively to give a trisubstituted succinic acid:




The trisubstituted succinic acid is then coupled to the N-heterocyclic moiety-containing derivative as described above. To produce the free acid, the benzyl ester is removed by hydrogenolysis to produce the corresponding acid. The acid can then be converted to the primary amide by methods well-known in the art.


An alternative method for preparing trisubstituted succinic acids involves reacting an ester of acetoacetic acid represented by the formula:




where R is a suitable protecting group, such as methyl, ethyl, benzyl or t-butyl with sodium hydride and a hydrocarbyl halide ($R^{31}X$ or $R^{32}X$) in a suitable solvent, e.g., THF, to produce the corresponding disubstituted derivative represented by the formula:



This disubstituted acetoacetic acid derivative is then treated with lithium diisopropyl amide at about $-10^{\circ}C$ and in the presence of $PhN(triflate)_2$ to produce a vinyl triflate of the formula:




The vinyl triflate is then carbonylated utilizing a palladium catalyst, e.g., $Pd(OAc)_2(Ph_3P)$, in the presence of an alcohol ($R''OH$) or water ($R''=H$) and a base, e.g., triethylamine, in a suitable solvent such as DMF, to produce the olefinic ester or acid of the formula:



5

The olefin can then be subsequently asymmetrically hydrogenated, as described above, to produce a trisubstituted succinic acid derivative of the formula:




15

If R'' is not H, R'' can be removed by either hydrolysis, acidolysis, or hydrogenolysis, to afford the corresponding acid, which is then coupled to the N-heterocyclic moiety-containing derivative as described above and then, optionally, the R group removed to produce the corresponding acid, and optionally, converted to the amide.


Alternatively, one can react the N-heterocyclic moiety-containing derivative with either a suitably monoprotected succinic acid or glutaric acid of the following structures;

30



5

followed by removal of the protecting group and
conversion of the resulting acid to an amide. One can
also react an anhydride of the following structure:



15

with the N-heterocyclic moiety-containing derivative and
then separate any isomers or convert the resulting acid
to an amide and then separate any isomers.

20

It is contemplated that for preparing compounds of the
Formulas having R⁶ being other than hydrogen, the
compounds can be prepared following the procedure set
forth above and, prior to coupling the N-heterocyclic
moiety-containing derivative to the respective acid, the
derivative carried through a procedure referred to in
the art as reductive amination. Thus, a sodium
cyanoborohydride and an appropriate aldehyde, such as
formaldehyde, acetaldehyde and the like, can be reacted
with the N-heterocyclic moiety-containing derivative

30

compound at room temperature in order to reductively aminate any of the compounds of Formulas I-IV.

Contemplated equivalents of the respective general formulas set forth above for the antiviral compounds and derivatives as well as the intermediates are compounds otherwise corresponding thereto and having the same general properties wherein one or more of the various R groups are simple variations of the substituents as defined therein, e.g., wherein R is a higher alkyl group than that indicated. In addition, where a substituent is designated as, or can be, a hydrogen, the exact chemical nature of a substituent which is other than hydrogen at that position, e.g., a hydrocarbyl radical or a halogen, hydroxy, amino and the like functional group, is not critical so long as it does not adversely affect the overall activity and/or synthesis procedure.

Optically active compound isomers as well as mixed or non-optically active compound isomers are specifically intended to be included in this discussion and in this invention. Examples of isomers are RS isomers, enantiomers, diastereomers, racemates, cis isomers, trans isomers, E isomers, Z isomers, syn-isomers, anti-isomers, tautomers and the like. Aryl, heterocyclo or heteroaryl tautomers, heteroatom isomers and ortho, meta or para substitution isomers are also included as isomers. Solvates or solvent addition compounds such as hydrates or alcoholates are also specifically included both as chemicals of this invention and in, for example, formulations or pharmaceutical compositions for delivery. In the propylene diamine (hydroxyethylamine)

function, a preferred configuration for the carbon bearing hydroxyl is R when the configuration at the carbon bearing the phenylthiomethylene group is R. A preferred set of isomers includes those depicted in the compounds of Examples 21 through 34 inclusive.


The chemical reactions described above are generally disclosed in terms of their broadest application to the preparation of the compounds of this invention.

Occasionally, the reactions may not be applicable as described to each compound included within the disclosed scope. The compounds for which this occurs will be readily recognized by those skilled in the art. In all such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate protection of interfering groups, by changing to alternative conventional reagents, by routine modification of reaction conditions, and the like, or other reactions disclosed herein or otherwise conventional, will be applicable to the preparation of the corresponding compounds of this invention. In all preparative methods, all starting materials are known or readily preparable from known starting materials.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

In the following examples, melting points were determined on a Fisher-Johns melting point apparatus and are uncorrected. All reagents were used as received without purification. All proton and carbon NMR spectra were
5 obtained on either a Varian VER-300 or VER-400 nuclear magnetic resonance spectrometer using tetramethysilane as internal standard. Gas chromatograph was performed on a Varian 3400 chromatography system. All instruments were utilized according to the manufacturer's directions.

Example 1: Preparation of N-Benzyloxycarbonyl-3(S)-amino-1,2(S)-epoxy-4-phenylbutane.




5

Part A:

To a solution of 75.0g (0.226 mol) of N-
benzyloxycarbonyl-L-phenylalanine chloromethyl
ketone in a mixture of 807 mL of methanol and 807 mL
of tetrahydrofuran at -2°C, was added 13.17g (0.348
mol, 1.54 equiv.) of solid sodium borohydride over
one hundred minutes. The solvents were removed in
vacuo at 40°C and the residue dissolved in ethyl
acetate (approx. 1L). The solution was washed
sequentially with 1M potassium hydrogen sulfate,
saturated sodium bicarbonate and then saturated
sodium chloride solutions. After drying over
anhydrous magnesium sulfate and filtering, the


solution was removed in vacuo. To the resulting oil was added hexane (approx. 1L) and the mixture warmed to 60°C with swirling. After cooling to room temperature, the solids were collected and washed with 2L of hexane. The resulting solid was recrystallized from hot ethyl acetate and hexane to afford 32.3g (43 % yield) of N-benzyloxycarbonyl-3(S)-amino-1-chlorophenyl-2(S)-butanol, mp 150-151°C and $M+Li^+ = 340$. formula:



Part B:

To a solution of 6.52g (0.116 mol, 1.2 equiv.) of potassium hydroxide in 968 mL of absolute ethanol at

room temperature, was added 32.3g (0.097 mol) of N-CBZ-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol, wherein CBZ stands for benzyloxycarbonyl. After stirring for fifteen minutes, the solvent was removed in vacuo and the solids dissolved in methylene chloride. After washing with water, drying over magnesium sulfate (MgSO_4), filtering and stripping, one obtains 27.9g of a white solid. Recrystallization from hot ethyl acetate and hexane afforded 22.3g (77% yield) of N-benzyloxycarbonyl-3(S)-amino-1,2(S)-epoxy-4-phenylbutane, mp 102-103°C and MH^+ 298; formula:




15

Example 2: Preparation of carbamic acid, [3-[3-
20 [[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-

isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-
phenylmethyl ester, [3S-[2(1R*,2S*), 3 α ,4 a β , 8
a β]]-. Also known as carbamic acid, [3-[3-[[[(1,1-
dimethylethyl)amino]carbonyl]decahydro-

5 isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-,
phenylmethyl ester, [3S-[2(1R*,2S*), 3a, 4 a β , 8
a β]]-.

10




Part A:

15


L-tetrahydroisoquinoline-2-carboxylic acid (24.83g,
0.140 mol) was suspended in a solution of 80 mL of
2.5 N sodium hydroxide, 80 mL of water, and 80 mL of
tetrahydrofuran. To this was added with vigorous

stirring, 32.0g (0.147 mol) of tert-butylpyrocarbonate in 20 mL of tetrahydrofuran. After 1 hour the pH dropped from 13 to 8.2, at pH = 7.8 sodium hydroxide (2.5 N) was added dropwise to maintain a pH of 8.8. After the pH stabilized, the contents were extracted with diethylether (2 x 125 mL). The aqueous phase was acidified (pH ~ 2.0) with more HCl, after cooling the solution in an ice bath. The precipitate was extracted with ether, which was then dried over MgSO₄, filtered and concentrated to yield 36.8 grams of crude product which needed no purification (95 % yield). The product was N-tert-butoxycarbonyl-L-tetrahydroisoquinoline-2-carboxylic acid which has the following formula:



Part B:

N-tert-butoxycarbonyl-L-tetrahydroisoquinoline-2-
5 carboxylic acid (27.7g, 0.10 moles) was dissolved in
50 mL of dimethylformamide, and to this was added a
warmed solution of 21 g of N-hydroxybenzotriazole in
30 mL of dimethylformamide. The solution was cooled
to 10°C and to this was added 19.1g (0.10 moles) of
10 1-(3-dimethylaminopropyl)-2-ethylcarbodiimide
hydrochloride (EDC) and the solution stirred for 10-
15 minutes, at which time 7.3g (0.100 moles) of
distilled tert-butylamine was added. After 14 hours
the solution was concentrated and 200 mL of ethyl
15 acetate was added. The organic layer was washed
with 5 % aqueous potassium hydrogen sulfate,
saturated sodium bicarbonate and brine, dried over
magnesium sulfate, filtered, and concentrated to
yield a yellow oil, which was crystallized from warm
20 hexane to yield 15.0 grams of a first crop (45.5 %
yield). The product was N-tert-butoxycarbonyl-S-
tetrahydroisoquinoline-2-carboxylic acid tert-butyl
amide which has the following formula:



5


Part C:

N-tert-butoxycarbonyl-S-tetrahydroisoquinoline-2-carboxylic acid tert-butyl amide (10.0g, 30 mmol) was dissolved in 50 mL of methanol and placed in a Fisher Porter bottle with 3.2g of wet rhodium (50 wt % H₂O, 10 wt % rhodium on carbon). The bottle was purged with nitrogen, and charged with 50 psig hydrogen and heated to 50°C for 24 hours. The catalyst was removed by filtration and the methanol evaporated to yield a mixture of (S,S,S) desired isomer and (S,R,R) undesired isomer in a 2:1 ratio, respectively. The desired isomer (S,S,S,) was separated by column chromatography on silica gel

using a 15-20% ethyl acetate hexane gradient elution to yield 6.1 grams of pure isomer (66% yield). The product was N-tert-butyloxycarbonyl-

(S,S,S)decahydroisoquinoline-2-carboxylic acid,

5 tert-butylamide which has the following structure:



10

Part D:

N-tert-butyloxycarbonyl-(S, S,

S)decahydroisoquinoline-2-carboxylic acid, tert-

15 butylamide (6.3g, 18.6 mmol) was dissolved in 30 mL

of 4N HCl in dioxane and stirred under a nitrogen

atmosphere for 1 hour. The solvent was removed and


the white solid was suspended in 200 mL of

dichloromethane and washed several times with

20 saturated sodium bicarbonate. The dichloromethane

(CH₂Cl₂) layer was dried over magnesium sulfate, filtered, and concentrated to yield 3.68g of freebase (85 % yield). The amine product has the following structure:


5

10 Part E:

The amine from part D (3.68g, 15.4 mmol) and 4.58g (15.4 mmol) of epoxide from Example 1 were dissolved in 50 mL of isopropanol and refluxed under a nitrogen atmosphere for 48 hours. The isopropanol was removed and the crude solid was chromatographed on silica gel using methanol methylene chloride eluant to provide 8.0g of pure product (97% yield) identified as carbamic acid, [3-[3-[(1,1-dimethylethyl)amino]carbonyloctahyd-2(1H)-

isoquinolinyl]-2-hydroxy-1-(phenylmethyl)-propyl]-, phenylmethyl ester, [3S-[2(1R*,2S*), 3 α ,4 a β , 8 a β]]-.

5



Example 3: Alternate General Procedure for the

10 Synthesis of 1,3-Diamino-4-Phenyl-2-ol Derivatives

Step A:

A solution of L-phenylalanine (50.0 g, 0.302 mol),
 15 sodium hydroxide (24.2 g, 0.605 mol) and potassium carbonate (83.6 g, 0.605 mol) in water (500 mL) is heated to 97°C. Benzyl bromide (108.5 mL, 0.912 mol) is then slowly added (addition time ~25 minutes). The mixture is then stirred at 97°C for 30 minutes.

The solution is cooled to room temperature and extracted with toluene (2 x 250 mL). The combined organic layers are then washed with water, brine, dried over magnesium sulfate, filtered and concentrated to give an oil product. The crude product is then used in the next step without purification.

Step B:

10

The crude benzylated product of the above step is dissolved in toluene (750 mL) and cooled to -55°C. A 1.5 M solution of DIBAL-H in toluene (443.9 mL, 0.666 mol) is then added at a rate to maintain the temperature between -55°C to -50°C (addition time ~1 hour). The mixture is stirred for 20 minutes at -55°C. The reaction is quenched at -55°C by the slow addition of methanol (37 mL). The cold solution is then poured into cold (5°C) 1.5 N HCl solution (1.8 L). The precipitated solid (approx. 138 g) is filtered off and washed with toluene. The solid material is suspended in a mixture of toluene (400 mL) and water (100 mL). The mixture is cooled to

5°C, treated with 2.5 N NaOH (186 mL) and then stirred at room temperature until the solid is dissolved. The toluene layer is separated from the aqueous phase and washed with water and brine, dried
5 over magnesium sulfate, filtered and concentrated to a volume of 75 mL (89 g). Ethyl acetate (25 mL) and hexane (25 mL) are then added to the residue upon which the alcohol product begins to crystallize. After 30 minutes, an additional 50 mL hexane is
10 added to promote further crystallization. The solid is filtered off and washed with 50 mL hexane to give approximately 35 g of material. A second crop of material can be isolated by refiltering the mother liquor. The solids are combined and recrystallized
15 from ethyl acetate (20 mL) and hexane (30 mL) to give, in 2 crops, approximately 40 g (40% from L-phenylalanine) of analytically pure alcohol product. The mother liquors are combined and concentrated (34 g). The residue is treated with ethyl acetate and
20 hexane which provides an additional 7 g (~7% yield) of slightly impure solid product. Further optimization in the recovery from the mother liquor is probable.

Step C:

A solution of oxalyl chloride (8.4 mL, 0.096 mol) in
5 dichloromethane (240 mL) is cooled to -74°C . A
solution of DMSO (12.0 mL, 0.155 mol) in
dichloromethane (50 mL) is then slowly added at a
rate to maintain the temperature at -74°C (addition
time ~ 1.25 hours). The mixture is stirred for 5
10 minutes, followed by addition of a solution of the
alcohol (0.074 mol) in 100 mL of dichloromethane
(addition time ~ 20 minutes, temp. -75°C to -68°C).
The solution is stirred at -78°C for 35 minutes.
Triethylamine (41.2 mL, 0.295 mol) is then added
15 over 10 minutes (temp. -78° to -68°C) upon which the
ammonium salt precipitated. The cold mixture is
stirred for 30 minutes and then water (225 mL) is
added. The dichloromethane layer is separated from
the aqueous phase and washed with water, brine,
20 dried over magnesium sulfate, filtered and
concentrated. The residue is diluted with ethyl
acetate and hexane and then filtered to further
remove the ammonium salt. The filtrate is

concentrated to give the desired aldehyde product.

The aldehyde was carried on to the next step without purification.

- 5 Temperatures higher than -70°C have been reported in the literature for the Swern oxidation. Other Swern modifications and alternatives to the Swern oxidations are also possible.
- 10 A solution of the crude aldehyde 0.074 mol and chloriodomethane (7.0 mL, 0.096 mol) in tetrahydrofuran (285 mL) is cooled to -78°C . A 1.6 M solution of n-butyllithium in hexane (25 mL, 0.040 mol) is then added at a rate to maintain the
- 15 temperature at -75°C (addition time ~15 minutes). After the first addition, additional chloriodomethane (1.6 mL, 0.022 mol) is added again, followed by n-butyllithium (23 mL, 0.037 mol), keeping the temperature at -75°C . The mixture is
- 20 stirred for 15 minutes. Each of the reagents, chloriodomethane (0.70 mL, 0.010 mol) and n-butyllithium (5 mL, 0.008 mol) are added 4 more times over 45 minutes at -75°C . The cooling bath is


then removed and the solution warmed to 22°C over
1.5 hours. The mixture is poured into 300 mL of
saturated aq. ammonium chloride solution. The
tetrahydrofuran layer is separated. The aqueous
5 phase is extracted with ethyl acetate (1 x 300 mL).
The combined organic layers are washed with bane,
dried over magnesium sulfate, filtered and
concentrated to give a brown oil (27.4 g). The
product could be used in the next step without
10 purification. The desired diastereomer can be
purified by recrystallization at a subsequent step.
Alternately, the product could be purified by
chromatography.

15 The resulting epoxide can be substituted for the
epoxide used in Example 2, Part E.

β-Amino Acid Derivatives

20 Example 4: Preparation of carbamic acid, [3-[[[3-[3-
[[(1,1-dimethylethyl)-amino]carbonyl]octahydro-2(1
H)-isoquinolinyl]-2-hydroxy-1-(phenyl-
methyl)propyl]amino]-2-methyl-3-oxopropyl]-, (4-

methoxyphenyl)methyl ester, [3S-
[2[1R*(S*),2S*],3 α ,4a β ,8a β]]-.




5

Part A:

- 10 A solution of carbamic acid, [3-[3-[(1,1-dimethylethyl)amino]-carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)-propyl], phenylmethyl ester, [3S-[2(1R*,2S*),3 α ,4a β ,8a β]]- (1.00g, 1.87 mmol) in methanol (50 mL) was
- 15 hydrogenated in the presence of 0.50g (50% wt) of 10% Pd/charcoal for 19 1/2 hours at room temperature and 50 psig of H₂. The catalyst was removed by vacuum filtration through a short plug of celite and the solvent removed in vacuo to give 0.69g (92%) of

a white foam. Subsequently, the crude material was triturated with diethylether (Et₂O) to give 0.51g (68%) of a white powder. The amine product has the following formula:


5

10 Part B:


N-p-methoxybenzyloxycarbonyl- α -methyl- β -alanine (430.5 mg, 1.6 mmol) was dissolved in 2.0 mL of dimethyl formamide, and to this was added 326 mg (1.5 eq) of N-hydroxybenzotriazole and stirred until the solution was homogeneous. The solution was then cooled to 5°C and 308 mg (1.6 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide was added the reaction stirred for 20 minutes. A solution of 547 mg (1.6 mmol) of the amine from Part A in 5 mL

of dimethylformamide (DMF) was added to the solution and stirred for 16 hours. The dimethylformamide was removed by rotary evaporation and replaced with ethyl acetate. The organic layer was washed with water and saturated sodium bicarbonate, dried over magnesium sulfate, filtered and concentrated to yield 730 mg of crude product. Flash column chromatography on silica gel using ethyl acetate:dichloromethane:ethanol eluant 25:25:1 provided 250 mg of product (25% yield), M+H = 651, identified as carbamic acid, [3-[[3-[3-[[[(1,1-dimethylethyl)-amino]carbonyl]octahydro-2(1H)-isoquinoliny]]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2-methyl-3-oxopropyl]-, (4-methoxyphenyl)methyl ester, [3S-[2[1R*(S*),2S*], 3 α ,4 a β , 8 a β]]-.

Example 5: Preparation of 3-(4-methoxybenzyloxycarbonyl)amino-2(R)-methylpropionic acid also known as N-4-Methoxybenzyloxycarbonyl- α -methyl- β -alanine (N-Moz-AMBA) and N-p-methoxybenzyloxycarbonyl- α -methyl- β -alanine.



5 A. Preparation of 4(4-methoxybenzyl)itaconate




- 10 A 5 L three-necked round bottomed flask equipped
with constant pressure addition funnel, reflux
condenser, nitrogen inlet, and mechanical stirrer
was charged with itaconic anhydride (660.8g, 5.88
mol) and toluene (2300 mL). The solution was warmed
15 to reflux and treated with 4-methoxybenzyl alcohol
(812.4g, 5.88 mol) dropwise over a 2.6 hour period.
The solution was maintained at reflux for an
additional 1.5hr and then the contents were poured
into three 2 L Erlenmeyer flasks to crystallize.
20 The solution was allowed to cool to room temperature
whereupon the desired mono-ester crystallized. The
product was isolated by filtration on a Buchner

funnel and air dried to give 850.2g, 58%, of material with mp 83-85°C, a second crop, 17% was isolated after cooling of the filtrate in an ice bath. ¹H NMR (CDC13) 300 MHz 7.32(d, J=8.7 Hz, 2H),
5 6.91(d, J=8.7 Hz, 2H), 6.49(s, 1H), 5.85(s, 1H),
5.12(s, 2H), 3.83(s, 3H), 3.40(s, 2H).

B. Preparation of Methyl 4(4-methoxybenzyl)

Itaconate

10



15


A 5 L three-necked round bottomed flask equipped
20 with reflux condenser, nitrogen inlet, constant
pressure addition funnel and mechanical stirrer was
charged with 4(4-methoxybenzyl) itaconate (453.4g,
1.81 mol) and treated with 1,5-

diazabicyclo[4.3.0]non-5-ene (275.6g, 1.81 mol),
(DBN), dropwise so that the temperature did not rise
above 15°C. To this stirring mixture was added a
solution of methyl iodide (256.9g, 1.81 mol) in 250
5 mL of toluene from the dropping funnel over a 45
minute period. The solution was allowed to warm to
room temperature and stirred for an additional 3.25
hours.

10 The precipitated DBN hydroiodide was removed by
filtration, washed with toluene and the filtrate
poured into a separatory funnel. The solution was
washed with saturated aqueous NaHCO₃ (2 X 500 mL),
0.2N HCl (1 X 500 mL), and brine (2 X 500 mL), dried
15 over anhyd. MgSO₄, filtered, and the solvent removed
in vacuo. This gave a clear colorless oil, 450.2g,
94% whose NMR was consistent with the assigned
structure. ¹H NMR (CDCl₃) 300 MHz 7.30(d, J=8.7 Hz,
2H), 6.90(d, J=8.7 Hz, 2H), 6.34(s, 1H), 5.71(s,
20 1H), 5.09(s, 2H), 3.82(s, 3H), 3.73(s, 3H), 3.38(s,
2H). ¹³C MMR (CDCl₃) 170.46, 166.47, 159.51, 133.55,
129.97, 128.45, 127.72, 113.77, 66.36, 55.12, 51.94,
37.64.

C. Preparation of Methyl 4(4-methoxybenzyl)-2(R)-
methylsuccinate

5



10

A 500 mL Fisher-Porter bottle was charged with methyl 4(4methoxybenzyl)itaconate (71.1g, 0.269 mol), rhodium (R,R) DiPAMP catalyst (204mg, 0.269 mmol, 0.1 mol%) and degassed methanol (215 mL). The bottle was flushed 5 times with nitrogen and 5 times with hydrogen to a final pressure of 40 psi. The hydrogenation commenced immediately and after ca. 1 hour the uptake began to taper off, after 3 hours the hydrogen uptake ceased and the bottle was flushed with nitrogen, opened and the contents concentrated on a rotary evaporator to give a brown

oil that was taken up in boiling iso-octane (ca. 200 mL, this was repeated twice), filtered through a pad of celite and the filtrate concentrated in vacuo to give 66.6g, 93 % of a clear colorless-oil, ¹H MMR


5 (CDC13 300 MHz 7.30(d, J=8.7 Hz, 2H), 6.91(d, J=8.7 Hz, 2H), 5.08(s, 2H), 3.82(s, 3H), 3.67(s, 3H), 2.95(ddq, J=5.7, 7.5, 8.7 Hz, 1H), 2.79(dd, J=8.1, 16.5 Hz, 1H), 2.45(dd, J=5.7, 16.5 Hz, 1H), 1.23(d, J=7.5 Hz, 3H).

10

D. Preparation of Methyl 2(R)-methylsuccinate

A 3 L three-necked round-bottomed flask equipped with a nitrogen inlet, mechanical stirrer, reflux
15 condenser and constant pressure addition funnel was charged with methyl 4(4-methoxybenzyl) 2(R)-methylsuccinate (432.6g, 1.65 mol) and toluene (1200 mL). The stirrer was started and the solution treated with trifluoroacetic acid (600 mL) from the
20 dropping funnel over 0.25 hours. The solution turned a deep purple color and the internal temperature rose to 45°C. After stirring for 2.25 hours the temperature was 27°C and the solution had

acquired a pink color. The solution was concentrated on a rotary evaporator. The residue was diluted with water (2200 mL) and sat. aq. NaHCO_3 (1000 mL). Additional NaHCO_3 was added until the acid had been neutralized. The aqueous phase was extracted with ethyl acetate (2 X 1000 mL) to remove the by-products and the aqueous layer was acidified to pH=1.8 with conc. HCl . This solution was extracted with ethyl acetate (4 X 1000 mL), washed with brine, dried over anhyd. MgSO_4 , filtered and concentrated on a rotary evaporator to give a colorless liquid 251g, > 100%, that was vacuum distilled through a short path apparatus cut 1: bath temperature 120°C @ 1mm, bp $25-29^\circ\text{C}$; cut 2: bath temperature 140°C @ 0.5mm, bp $95-108^\circ\text{C}$, 151g, $[\alpha]_D^{25} = +1.38^\circ\text{C}$ (c=15.475, MeOH), $[\alpha]_D = +8.48^\circ\text{C}$ (neat); cut 3: bath temperature 140°C , bp 108°C , 36g, $[\alpha]_D^{25} = +1.49^\circ\text{C}$ (c=15.00, MeOH), $[\alpha]_D = +8.98^\circ\text{C}$ (neat). Cuts 2 and 3 were combined to give 189g, 78% of product, ^1H NMR (CDCl_3) 300 MHz 11.6(brs, 1H), 3.72(s, 3H), 2.92(ddq, J=5.7, 6.9, 8.0 Hz, 1H), 2.81(dd, J=8.0, 16.8 Hz, 1H), 2.47(dd, J=5.7, 16.8 Hz, 1H), 1.26(d, J=6.9 Hz, 3H).

E. Preparation of Methyl Itaconate

10 A 50 mL round bottomed flask equipped with reflux
condenser, nitrogen inlet and magnetic stir bar was
charged with methyl 4(4-methoxybenzyl) itaconate
(4.00g, 16 mmol), 10 mL of toluene and 10 mL of
trifluoroacetic acid. The solution was kept at room
15 temperature for 18 hours and then the volatiles were
removed in vacuo. The residue was taken up in ethyl
acetate and extracted three times with saturated
aqueous sodium bicarbonate solution. The combined
aqueous extract was acidified to pH= 1 with aqueous
20 potassium bisulfate and then extracted three times
with ethyl acetate. The combined ethyl acetate
solution was washed with saturated aqueous sodium
chloride, dried over anhydrous magnesium sulfate,


filtered, and concentrated in vacuo. The residue was then vacuum distilled to give 1.23g, 75% of pure product, bp 85-87 @ 0.1 mm. ^1H NMR (CDCl₃) 300 MHz 6.34(s, 1H), 5.73(s, 2H), 3.76(s, 3H), 3.38(s, 2H).
5 ^{13}C NMR (CDCl₃) 177.03, 166.65, 129.220, 132.99, 52.27, 37.46.

F. Curtius Rearrangement of Methyl 2(R)-methylsuccinate:

10

Preparation of Methyl N-Moz- α -methyl β -alanine.

15




20

A 5L four necked round bottomed flask equipped with a nitrogen inlet, reflux condenser, mechanical stirrer, constant pressure addition funnel, and

thermometer adapter was charged with methyl 2(R)-
methylsuccinate (184.1g, 1.26 mol), triethylamine
(165.6g, 218 mL, 1.64 mol, 1.3 equivalents), and
toluene (1063 mL). The solution was warmed to 85°C
5 and then treated dropwise with a solution of
diphenylphosphoryl azide (346.8g, 1.26 mol) over a
period of 1.2 hours. The solution was maintained at
that temperature for an additional 1.0 hour and then
the mixture was treated with 4-methoxybenzyl alcohol
10 (174.1g, 1.26 mol) over a 0.33 hours period from the
dropping funnel. The solution was stirred at 88°C
for an additional 2.25 hours and then cooled to room
temperature. The contents of the flask were poured
into a separatory funnel and washed with saturated
15 aqueous NaHCO₃ (2 X 500 mL), 0.2N HCl (2 X 500 mL),
brine (1 X 500 mL), dried over anhydrous MgSO₄,
filtered, and concentrated in vacuo to give 302.3g,
85 % of the desired product as a slightly brown oil.
¹H NMR (CDCl₃) 300 MHz 7.32(d, J=8.4 Hz, 2H), 6.91(d,
20 J=8.4 Hz, 2H), 5.2(brm, 1H), 5.05(s, 2H), 3.83(s,
3H), 3.70(s, 3H), 3.35(m, 2H), 2.70(m, 2H), 1.20(d,
J=7.2 Hz, 3H).

G. Hydrolysis of Methyl N-Moz- α -methyl- β -alanine:Preparation of α -methyl β -alanine Hydrochloride

5




10

A 5 L three-necked round bottomed flask equipped with a reflux condenser, nitrogen inlet and mechanical stirrer was charged with methyl N-Moz- α -methyl- β -alanine (218.6g, 0.78 mol), glacial acetic acid (975 mL) and 12N hydrochloric acid (1960 mL). The solution was then heated to reflux for 3h. After the solution had cooled to room temperature (ca. 1 hour) the aqueous phase was decanted from organic residue (polymer) and the aqueous phase concentrated on a rotary evaporator. Upon addition of acetone to the concentrated residue a slightly yellow solid formed that was slurried with acetone

and the white solid was isolated by filtration on a Buchner funnel. The last traces of acetone were removed by evacuation to give 97.7g, 90% of pure product, mp 128.5-130.5°C $[\alpha]_D^{25} = 9.0^\circ$ (c=2.535,

5 Methanol). ¹H NMR (D₂O) 300 MHz 3.29(dd, J=8.6, 13.0 Hz, 1H), 3.16(dd, J=5.0, 13.0m Hz, 1H), 2.94(ddq, J=7.2, 5.0, 8.6 Hz, 1H), 1.30(d, J=7.2 Hz, 3H); ¹³C NMR (D₂O) 180.84, 44.56, 40.27, 17.49.

10 H. Preparation of N-Boc α-Methyl-β-Alanine



15


A solution of α-Methyl-β-Alanine hydrochloride (97.7g, 0.70 mol) in water (1050 mL) and dioxane (1050 mL) the pH was adjusted to 8.9 with 2.9N NaOH solution. This stirring solution was then treated with di-tert-butyl pyrocarbonate (183.3g, 0.84 mol, 1.2 equivalents) all at once. The pH of the

solution was maintained between 8.7 and 9.0 by the periodic addition of 2.5N NaOH solution. After 2.5h the pH had stabilized and the reaction was judged to be complete. The solution was concentrated on a rotary evaporator (the temperature was maintained at <40°C). The excess di-t-butyl pyrocarbonate was removed by extraction with dichloromethane and then the aqueous solution was acidified with cold 1N HCl and immediately extracted with ethyl acetate (4 X 1000 mL). The combined ethyl acetate extract was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated on a rotary evaporator to give a thick oil 127.3g, 90% crude yield that was stirred with n-hexane whereupon crystals of pure product formed, 95.65g, 67%, mp 76-78°C, [α]_D @ 25°C = -11.8°C (c=2.4, EtOH). A second crop was obtained by concentration of the filtrate and dilution with hexane, 15.4g, for a combined yield of 111.05g, 78%. ¹H NMR (acetone D₆) 300 MHz 11.7 (brs, 1H), 6.05 (brs 1H), 3.35 (m, 1H), 3.22 (m, 1H), 2.50 (m, 1H), 1.45(s, 9H), 1.19 (d, J=7.3 Hz, 3H); ¹³C NMR (acetone D₆) 177.01, 79.28, 44.44, 40.92, 29.08, 15.50. Elemental analysis calc'd. for C₅H₇NO₄: C,

53.19, H, 8.42; N 6.89. Found: C, 53.36; H, 8.46; N, 6.99.

I. Preparation of N-4-Methoxybenzyloxycarbonyl- α -

5 Methyl- β -Alanine



15

A solution of N-4-methoxybenzyloxycarbonyl- α -methyl- β -alanine methyl ester (2.81g, 10.0 mmol) in 30 mL of 25% aqueous methanol was treated with lithium hydroxide (1.3 equivalents) at room temperature for a period of 2 hours. The solution was concentrated in vacuo and the residue taken up in a mixture of water and ether and the phases separated and the organic phase discarded. The aqueous phase was

20

acidified with aqueous potassium hydrogen sulfate to pH=1.5 and then extracted three times with ether.

The combined ethereal phase was washed with

saturated aqueous sodium chloride solution, dried

5 over anhydrous magnesium sulfate, filtered and

concentrated in vacuo to give 2.60 g, 97% of N-4-

methoxybenzyloxycarbonyl- α -methyl- β -alanine (N-Moz-AMBA) which was purified by recrystallization from a

mixture of ethyl acetate and hexane to give 2.44g,

10 91%, of pure product, mp 96-97°C, $MH^+=268$. 1H NMR (D₅-acetone/300 MHz) 1.16 (3H, d, J=7.2Hz), 2.70 (1H, m), 3.31 (2H, m), 3.31 (3H, s), 4.99 (2H, s), 6.92 (2H, 4, J=8.7 Hz), 7.13 (2H, d, J=8.7 Hz).


15 Sulfone Derivatives

Example 6: Preparation of 3-Isoquinolinecarboxamide,

N-(1,1-dimethylethyl)decahydro-2-[2-hydroxy-3-[[2-methyl-3-(methylsulfonyl)-1-oxopropyl]amino]-4-

20 phenylbutyl]-, [3S-[2[2S*,3R*(R*)], 3 α , 4 $\alpha\beta$, 8 $\alpha\beta$]]-.

Part A:



10


A solution of carbamic acid, [3-[3-[(1,1-
 15 dimethylethyl)amino]-carbonyl]octahydro-2(1H)-
 isoquinolinyl]-2-hydroxy-1-(phenylmethyl)-propyl]-
 phenylmethyl ester, [3S-[2(1R*,2S*), 3 α , 4 β , 8 $\alpha\beta$]]-
 (1.00g, 1.87 mmol) in methanol (50 mL) was
 hydrogenated in the presence of 0.50g (50% wt) of
 20 10% Pd/charcoal for 19 1/2 hours at room temperature
 and 50 psig of H₂. The catalyst was removed by
 vacuum filtration through a short plug of celite and
 the solvent removed in vacuo to give 0.69g (92%) of

a white foam. Subsequently, the crude material was triturated with diethylether (Et_2O) to give 0.51g (68%) of a white powder. The amine product has the following formula:

5

Part B:

10




15

20

To a solution of 230 mg (1.38 mmol) of 2(S)-methyl-3-(methylsulfonyl)propionic acid in anhydrous DMF (4

mL) was added N-hydroxybenzotriazole (HOBT) (290 mg, 2.15 mmol) as a powder and EDC (390 mg, 2.03 mmol) as a powder. The resulting solution was stirred under nitrogen for 10 minutes upon which was added 5 500 mg (1.24 mmol) of amine from part A in DME (6 mL) and stirring continued for 17 hours. Subsequently, the reaction mixture was poured into 50% saturated NaHCO₃ (aq) and chilled for 1 hour, upon which a pale precipitate formed, which was 10 filtered, washed with water and dried under reduced pressure to give 430 mg (63%) of a pale powder. The crude material was chromatographed on silica, gel eluting with 5% ethanol in ethyl acetate to give 80 mg (12%) of 3-isoquinolinecarboxamide, N-(1,1- 15 dimethylethyl)decahydro-2-[2-hydroxy-3-[[2-methyl-3-(methylsulfonyl)-1-oxopropyl]amino]-4-phenylbutyl]-, [3S-[2[2S*,3R*(R*)], 3 α , 4 $\alpha\beta$, 8 $\alpha\beta$]]- as a white powder; mass spectrum, m/e 556 (FAB, M + Li).




10

The 2(S)-methyl-3-(methylsulfonyl)propionic acid
(see Example 7 for preparation) may be substituted
15 by sulfonyl alkyl acids, for example, 2-(R,S)methyl-
3-(methylsulfonyl)propionic acid (see Example 8 for
preparation) and 2-(R,S)-methyl-3(β -
phenethylsulfonyl)-propionic acid (see Example 9 for
preparation).

20


Example 7: Preparation of 2(S)-methyl-3-
(methylsulfonyl)Propionic Acid.



5

To a solution of 10g of D-(-)-S-benzoyl-β-
10 mercaptioisobutyric acid t-butyl ester in 20 mL of
methanol was bubbled in gaseous ammonia at 0°C. The
reaction was allowed to then warm to room
temperature, stirred overnight and concentrated in
vacuo. The resulting mixture of a solid (benzamide)
15 and liquid was filtered to provide 5.21g of a pale
oil which then solidified. This was identified as
2(S)-methyl-3-mercaptopropionic acid t-butyl ester:


20



5


10 To a solution of 5.21g of 2(S)-methyl-3-
mercaptopropionic acid t-butyl ester in 75 mL of
toluene at 0°C was added 4.50g of 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) and 1.94 mL of
methyl iodide. After stirring at room temperature
15 for 2.5 hours, the volatiles were removed, ethyl
acetate added, washed with dilute hydrochloric acid,
water, brine, dried and concentrated to afford 2.82g
of a pale oil, identified as 2(S)-methyl-3-
(thiomethyl)propionic acid t-butyl ester:

20




5

To a solution of 2.82g of 2(S)-methyl-3-(thiomethyl)propionic acid t-butyl ester in 50 mL of acetic acid was added 5.58g of sodium perborate and the mixture heated to 55°C for 17 hours. The reaction was poured into water, extracted with methylene chloride, washed with aqueous sodium bicarbonate, dried and concentrated to afford 2.68g of 2(S)-methyl-3-(methylsulfonyl)propionic acid t-butyl ester as a white solid:




20

To 2.68g of 2(S)-methyl-3-(methylsulfonyl)propionic acid t-butyl ester was added 20 mL of 4N hydrochloric acid/dioxane and the mixture stirred at room temperature for 19 hours. The solvent was removed in vacuo to afford 2.18g of crude product, which was recrystallized from ethyl acetate/hexane to yield 1.44g of 2(S)-methyl-3-(methylsulfonyl)-propionic acid as white crystals:




Example 8: Preparation of 2-(R,S)-Methyl-3-(methylsulfonyl)propionic acid by Asymmetric Hydrogenation.



Part A:

5

A solution of methyl 2-(bromomethyl)-acrylate (26.4 g, 0.148 mol) in 100 mL of methanol was treated with sodium methanesulfinate (15.1 g, 0.148 mol) portion wise over 10 minutes at room temperature. The solution was then stirred at room temperature for a period of 1.25 hours and the solution concentrated in vacuo. The residue was then taken up in water and extracted four times with ethyl acetate. The combined ethyl acetate solution was washed with saturated sodium chloride, dried over anhydrous magnesium sulfate, filtered and concentrated to give a white solid, 20.7 g, which was taken up in boiling acetone/methyl t-butyl ether and allowed to stand whereupon crystals of pure methyl 2-(methanesulfonylmethyl) acrylate 18.0 g, 68% formed, mp 65-68°C. Formula:




10 Part B:

A solution of methyl 2-(methylsulfonylmethyl)
acrylate (970 mg, 5.44 mmol) in 15 mL of
tetrahydrofuran was treated with a solution of
15 lithium hydroxide (270 mg, 6.4 mmol) in 7 mL of
water. The solution was stirred at room temperature
for 5 minutes and then acidified to pH=1 with 1 N
aqueous potassium hydrogen sulfate and the solution
extracted three times with ethyl acetate. The
20 combined ethyl acetate solution was dried over
anhydrous magnesium sulfate, filtered, and
concentrated to give 793 mg, 89 % of 2-

(methylsulfonylmethyl) acrylic acid, mp 147-149°C.;

formula:

5




10

Part C:

A solution of 2-(methylsulfonylmethyl) acrylic acid (700 mg, 4.26 mmol) in 20 mL of methanol was charged into a Fisher-Porter bottle along with 10% palladium on carbon catalyst under a nitrogen atmosphere. The reaction vessel was sealed and flushed five times with nitrogen and then five times with hydrogen. The pressure was maintained at 50 psig for 16 hours and then the hydrogen was replaced with nitrogen and the solution filtered through a pad of celite to remove the catalyst and the filtrate concentrated in

vacuo to give 682 mg, 96%, of 2-(R,S)methyl-3-methylsulfonyl propionic acid; formula:


5



10

Example 9: Preparation of Sulfones by Michael Addition to Methyl Methacrylate.

15




20

Part A:

A solution of methyl methacrylate (7.25 g, 72.5 mmol) and phenethyl mercaptan (10.0 g, 72.5 mmol) in 100 mL of methanol was cooled in an ice bath and treated with sodium methoxide (100 mg, 1.85 mmol).

- 5 The solution was stirred under nitrogen for 3 hours and then concentrated in vacuo to give an oil that was taken up in ether and washed with 1 N aqueous potassium hydrogen sulfate, saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate,
- 10 filtered and concentrated to give 16.83 g, 97.5% of methyl 2-(R,S)-methyl-4-thia-6-phenyl hexanoate as an oil. TLC on SiO₂ eluting with 20:1 hexane:ethyl acetate (v:v) R_f=0.41. Formula:

15




20

Part B:

A solution of methyl 2-(R,S)-methyl-thia-6-phenyl
hexanoate (4.00 g, 16.8 mmol) in 100 mL of
5 dichloromethane was stirred at room temperature and
treated portion wise with meta-chloroperoxybenzoic
acid (7.38 g, 39.2 mmol) over approximately 40
minutes. The solution was stirred at room
temperature for 16 hours and then filtered and the
10 filtrate washed with saturated aqueous sodium
bicarbonate, 1N sodium hydroxide, saturated aqueous
sodium chloride, dried over anhydrous magnesium
sulfate, filtered, and concentrated to give 4.50 g,
99% of desired sulfone. The unpurified sulfone was
15 dissolved in 100 mL of tetrahydrofuran and treated
with a solution of lithium hydroxide (1.04 g, 24.5
mmol) in 40 mL of water. The solution was stirred
at room temperature for 2 minutes and then
concentrated in vacuo. The residue was then
20 acidified with 1N aqueous potassium hydrogen sulfate
to pH=1 and then extracted three times with ethyl
acetate. The combined ethyl acetate solution was
washed with saturated aqueous sodium chloride, added

over anhydrous magnesium sulfate, filtered and concentrated to give a white solid. The solid was taken up in boiling ethyl acetate/hexane and allowed to stand undisturbed whereupon white needles formed that were isolated by filtration and air added to give 3.38 g, 79% of 2-(R,S)methyl-3(phenethylsulfonyl)-propionic acid, mp 91-93°C.; formula:



β-Asparagine Derivatives


Example 10: Preparation of butanediamide, N'-[3-[3-[[[(1,1-dimethylethyl)-amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-

(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [3S[2[1R*(R*),2S*],3 α ,4a β ,8a β]]-.

5

10

15




20

Part A:

A solution of carbamic acid, [3-[3-[(1,1-dimethylethyl)-amino]carbonyl]octahydro-2(1H)-isoquinoliny]l]-2-hydroxy-1-(phenylmethyl)propyl],
5 phenylmethyl ester, [3S-[2(1R*,2S*),3 α ,4 α β ,8 α β]]-(1.2g, 2.2 mmol) in 50 mL of methanol was charged to a Fisher Porter tube. The contents were purged with nitrogen and 300 mg, 25 wt % of 10% palladium on carbon was carefully added. The solution was
10 charged with 50 psig hydrogen and was vigorously stirred for 2.5 hours. The catalyst was removed by filtration and the solution was concentrated to yield 849 mg (96% yield) of pure amine which has the following formula:

15




5

Part B:

N-(2-quinolinylcarbonyl)-L-isoasparagine (366 mg, 1.2 mmol) was dissolved in 4.0 mL of dry dimethylformamide, and to this was added 250 mg (1.8 mmol) of N-hydroxybenzotriazole. After the solution was homogeneous, 230 mg (1.2 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide was added and the reaction stirred for 15 minutes. A solution of 510 mg (1.2 mmol) of amine from part A was added in 4.0 mL of dimethylformamide to the solution and stirred for 16 hours. The majority of solvent was removed and replaced with ethyl acetate. The organic phase was extracted with water, saturated sodium bicarbonate and concentrated to yield 693 mg of white foam. Flash chromatography on silica gel using a gradient elution from 5 % to 10% methanol/dichloromethane gave 346 mg of pure product, identified as butanediamide, N⁴-[3-[3-

[[(1,1-dimethylethyl)-amino]carbonyl]octahydro-
 2(1H)-isoquinolinyl]-2-hydroxy-1-
 (phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)-
 amino]-, [3S-[2[1R*(R*),2S*],3 α ,4 α β ,8 α β]]-.


5 M+Li=677.3. Formula:



15

20

Example 11: Preparation of N-(2-Quinolinylcarbonyl)-
 L-isoasparagine.



5

10


To a solution of 0.50g (3.78 mmol) of L-isoasparagine in 5.0 mL H₂O containing ~45 mg (1.5 eq) of solid bicarbonate. To this was added a suspension of 1.02g (3.78 mmol) quinaldic acid, N-hydroxysuccinamide ester in ethylene glycol dimethylether, and the suspension was solubilized by the addition of 10 mL of dimethylformamide. After 3 hours the solution was acidified by the addition of 5% HCl (aqueous) and the product was filtered and washed with water, dried under vacuum to yield 750 mg (70% yield) of N-(2-quinolinylcarbonyl)-L-isoasparagine.

15

20

Succinamide Derivatives


Example 12: Preparation of Butanamide, 4-[[3-[3-
 5 [[(1,1-dimethylethyl)-amino]carbonyl]octahydro-
 2(1H)-isoquinoliny]]-2-hydroxy-1-
 (phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-
 , [3S-[2[1R*(S*),2S*], 3 α ,4 a β ,8a β]]-.



Part A:

A solution of carbamic acid, [3-[3-1[(1, 1-
dimethylethyl)amino]carbonyl]octahydro-2(1H)-
isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-
5 ,phenylmethyl ester, [3S-[2(1R*,2S*),3 α ,4 a β ,8a β]]-
(1.2g, 2.2 mmol) was dissolved in 50 mL of methanol
and charged to a Fisher Porter tube. The contents
were purged with nitrogen and 300 mg, 25 wt % of 10%
palladium on carbon was carefully added. The
10 solution was charged with 50 psig hydrogen and was
vigorously stirred for 2.5 hours. The catalyst was
removed by filtration and the solution was
concentrated to yield 849 mg (96% yield) of pure
amine having the following formula:

15




5

Part B:

To a solution of benzyl 2,2,3(R)-trimethylsuccinate
(125 mg, 0.5 mmol) in DMF (1.5 mL) was added HOBt
10 (153 mg, 1.0 mmol). After all the solid was
dissolved, the solution was cooled to 0°C and to
this was added EDC (143 mg, 0.75 mmol) and stirring
was continued to 2 hours at 0°C. To this cold
solution was added 200 mg (0.5 mmol) of amine from
15 part A and stirred at 0°C for 2 hours and room
temperature for 32 hours. The solvents were removed
in vacuo (less than or equal to 40°C) and the
residue was dissolved in ethyl acetate (5 mL). This
solution was washed with 60% sat. NaHCO₃ (2 mL x 2),
20 5% citric acid (2 mL) and sat. NaCl (2 mL x2). The
combined organic layers were dried (Na₂SO₄) and
concentrated to give a white solid. The
purification of the crude product by flash

chromatography (silica gel, 4% MeOH/CH₂Cl₂) gave 188
mg (59%) of the desired product as a white solid,
[M+Li]⁺=640, identified as butanoic acid, 4-[[3-[3-[3-
[[1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-
5 isoquinolinyl]-2-hydroxy-1-
(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-,
phenylmethyl ester, [3S-[2[1R*(S*),2S*],3α,4aβ, 8a
β]]-; formula:




Part C:

5

A mixture of benzyl ester from part B (180 mg, 0.284 mmol), 10% Pd/C (125 mg) in methanol (MeOH) (2 mL) was hydrogenated (H_2 , 50 psi) at room temperature for 30 minutes. The solid was filtered and was washed with MeOH (3 mL x 2). The combined filtrates were concentrated to give 122 mg (79%) acid as a pale yellow solid, $[M+H]^+=544$ and $[M+Li]^+=550$, identified as butanoic acid, 4-[[3-[3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [3S-[2[1R*(S*), 2S*], 3 α , 4 α , 8 β]]-; formula:

20




5

Part D:

10

To a solution of acid from part C (120 mg, 0.22 mmol) in DMF (0.5 mL) was added HOBt (68 mg, 0.44 mmol), NH_4Cl (11.8 mg, 0.22 mmol) at room temperature. After all the solid was dissolved, to 15 the solution was added LDC (63 mg, 0.33 mmol) at 0°C and stirred at the temperature for 2 hours. To this cold solution was added 30% NH_4OH (0.124 mL, 1.1 mmol) dropwise and the resulting mixture was stirred at 0°C for 6 hours and at room temperature for 16 20 hours. The solvents were removed in vacuo (less than or equal to 40°C) and the residue was dissolved in ethyl acetate (5 mL). The solution was washed with 60% sat. NaHCO_3 (2 mL x 2), 5 % citric acid (2


mL) and sat. NaCl (2 mL x 2). The combined organic layers were dried (Na₂SO₄) and concentrated to give a white solid. The purification of crude product by flash chromatography (silica gel, 5% MeOH/CH₂Cl₂) gave 72 mg (60%) of pure amide, [M+H]⁺=543, identified as Preparation of Butanamide, 4-[[3-[3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro]2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2,2,3-trimethyl-4-oxo-, [3S-[2[1R*(S*),2S*],3α,4aβ,8aβ]]-; formula:



In Example 12, part B, the benzyl 2,2,3(R)-
trimethylsuccinate (see Example 13 for preparation)
may be substituted by the various succinates,
succinamides and itaconamides produced in Examples
5 13 through 20 infra. in the appropriate amounts the
determination of which is within the skill of the
art.

Example 13: Preparation of Benzyl 2,2,3(R)-
10 trimethylsuccinate


15



20

Part A: Preparation of Methyl (S)-lactate, 2-methoxy-2-propyl ether.


5



10

To a mixture of methyl-(S)-(-)-lactate (13.2g, 100 mmol) and 2-methoxypropene (21.6g, 300 mmol) in CH_2Cl_2 (150 mL) was added POCl_3 (about 1.5 mL) at room temperature and the resulting mixture was stirred at this temperature for 16 hours. After the addition of triethylamine (NEt_3) (about 2 mL), the solvents were removed in vacuo to give 20.0g of (98%) desired product.

Part B: Preparation of 2(S)-hydroxypropanal, 2-methoxy-2-propyl ether.




10

To a solution of compound from Part A (20.0g) in CH_2Cl_2 (100 mL) was added diisobutyl aluminum hydride (DIBAL) (65 mL of 1.5M solution in toluene, 97.5 mmol) dropwise at -78°C for 45 minutes, then stirring was continued at the temperature for another 45 minutes. To this cold solution was added MeOH (20 mL), saturated NaCl solution (10 mL) and allowed the reaction mixture to warm up to room temperature and diluted with ether (200 mL), MgSO_4 (150g) was added and stirred for another 2 hours. The mixture was filtered and the solid was washed twice with ether. The combined filtrates were

rotavaped to afford 11.2g (78%) of the desired aldehyde.

Part C: Preparation of 2(S)-hydroxy-cis-3-butene, 2-methoxy-2-propyl ether.




10

To a suspension of ethyltriphenylphosphonium bromide (28g, 75.5 mmol) in THF (125 mL) was added potassium bis(trimethylsilyl)amide ($\text{KN}(\text{TMS})_2$) (15.7g, 95%, 75 mmol) in portions at 0°C and stirred for 1 hour at the temperature. This red reaction mixture was cooled to -78°C and to this was added a solution of aldehyde from Part B (11g, 75 mmol) in THF (25 mL). After the addition was completed, the resulting reaction mixture was allowed to warm up to room temperature and stirred for 16 hours. To this

mixture was added saturated NH_4Cl (7.5 mL) and filtered through a pad of celite with a thin layer of silica gel on the top. The solid was washed twice with ether. The combined filtrates were
5 concentrated in vacuo to afford 11.5g of crude product. The purification of crude product by flash chromatography (silica gel, 10:1 Hexanes/ethyl acetate) affording 8.2g (69%) pure alkene.

10 Part D: Preparation of 2(S)-hydroxy-cis-3-butene.



15


20 A mixture of alkene from Part C (8.2g) and 30% aqueous acetic acid (25 mL) was stirred at room temperature for 1 hour. To this mixture was added NaHCO_3 slowly to the pH ~ 7, then extracted with

ether (10 mL x 5). The combined ether solutions were dried (Na_2SO_4) and filtered. The filtrate was distilled to remove the ether to give 2.85g (64%) pure alcohol, $m/e=87(M+H)$.

5

Part E: Preparation of 2,2,3-trimethyl-hex-(trans)-4-enoic acid.

10




15

To a mixture of alcohol from Part D (2.5g, 29 mmol) and pyridine (2.5 mL) in CH_2Cl_2 (60 mL) was added isobutyryl chloride (3.1g, 29 mmol) slowly at 0°C . The resulting mixture was stirred at room temperature for 2 hours then washed with H_2O (30 mL x 2) and sat. NaCl (25 mL). The combined organic

phases were dried (Na_2SO_4), concentrated to afford 4.2g (93%) ester 2(S)-hydroxy-cis-3-butenyl isobutyrate. This ester was dissolved in THF (10 mL) and was added to a 1.0M lithium diisopropylamide (LDA) solution (13.5 mL of 2.0M LDA solution in THF and 13.5 mL of THF) slowly at -78°C . The resulting mixture was allowed to warm up to room temperature and stirred for 2 hours and diluted with 5 % NaOH (40 mL). The organic phase was separated, the aqueous phase was washed with Et_2O (10 mL). The aqueous solution was collected and acidified with 6N HCl to pH ~3. The mixture was extracted with ether (30 mL x 3). The combined ether layers were washed with sat. NaCl (25 mL), dried (Na_2SO_4) and concentrated to afford 2.5g (60%) of desired acid, $m/e=157(\text{M}+\text{H})$.

Part F: Preparation of benzyl 2,2,3(S)-trimethyl-trans-4-hexenoate.




5

A mixture of acid from Part E (2.5g, 16 mmol), benzylbromide (BnBr) (2.7g, 15.8 mmol), K_2CO_3 (2.2g, 16 mmol), NaI (2.4g) in acetone (20 mL) was heated at 75°C (oil bath) for 16 hours. The acetone was stripped off and the residue was dissolved in H_2O (25 mL) and ether (35 mL). The ether layer was separated, dried (Na_2SO_4) and concentrated to afford 3.7g (95 %) of benzyl ester, $m/e=247(M+H)$.

Part G: Preparation of benzyl 2,2,3(R)-trimethylsuccinate.


20



- 5 To a well-stirred mixture of KMnO_4 (5.4g, 34, 2 mmol), H_2O (34 mL), CH_2Cl_2 (6 mL) and benzyltriethylammonium chloride (200 mg) was added a solution of ester from Part F (2.1g, 8.54 mmol) and acetic acid (6 mL) in CH_2Cl_2 (28 mL) slowly at 0°C .
- 10 The resulting mixture was stirred at the temperature for 2 hours then room temperature for 16 hours. The mixture was cooled in an ice-water bath, to this was added 6N HCl (3 mL) and solid NaHSO_3 in portions until the red color disappeared. The clear solution
- 15 was extracted with CH_2Cl_2 (30 mL x 3). The combined extracts were washed with sat. NaCl solution, dried (Na_2SO_4) and concentrated to give an oil. This oil was dissolved in Et_2O (50 mL) and to this was added sat. NaHCO_3 (50 mL). The aqueous layer was separated
- 20 and acidified with 6N HCl to pH about 3 then extracted with Et_2O (30 mL x 3). The combined extracts were washed with sat. NaCl solution (15 mL), dried (Na_2SO_4) and concentrated to afford 725 mg


(34%) of desired acid, benzyl 2,2,3(R)-
trimethylsuccinate, $m/e = 251$ (M +H).

Example 14: Preparation of methyl 2,2-dimethyl-3-
5 methyl succinate, (R) and (S) isomers.



10

Part A: Preparation of methyl 2,2-dimethyl-3-oxo-
15 butanoate.




20

A 250 mL RB flask equipped with magnetic stir bar and N₂ inlet was charged with 100 mL dry THF and 4.57g (180 mmol) of 95% NaH. The slurry was cooled to -20°C and 10g (87 mmol) methyl acetoacetate was added dropwise followed by 11.3 mL (181 mmol) CH₃I. The reaction was stirred at 0°C for 2 hours and let cool to room temperature overnight. The reaction was filtered to remove NaI and diluted with 125 mL Et₂O. The organic phase was washed with 1x100 L 5% brine, dried and concentrated in vacuo to a dark golden oil that was filtered through a 30g plug of silica gel with hexane. Concentration in vacuo yielded 10.05g of desired methyl ester, as a pale yellow oil, suitable for use without further purification.

Part B: Preparation of methyl 2,2-dimethyl-3-O-(trifluoromethanesulfonate)-but-3-eneoate.


20



A 250 ml RB flask equipped with magnetic stir bar and N₂ inlet was charged with 80 mL by THP and 5.25 mL (37.5 mmol) diisopropylamine was added. The solution was cooled to -25°C (dry ice/ethylene glycol) and 15 mL (37.5 mmol) of 2.5 M n-butyl lithium (n-BuLi) in hexanes was added. After 10 minutes a solution of 5g (35 mmol) of methyl 2,2-dimethyl-3-oxo-butanoate from Part A in 8 mL dry THF was added. The deep yellow solution was stirred at -20°C for 10 minutes then 12.4g N-phenyl-bis(trifluoromethanesulfonimide) (35 mmol) was added. The reaction was stirred at about -10°C for 2 hours, concentrated in vacuo and partitioned between ethyl acetate and sat. nacho. The combined organic phase was washed with NaHCO₃, brine and concentrated to an amber oil that was filtered through 60g silica gel plug with 300 mL 5% ethyl acetate/hexane. Concentration in vacuo yielded 9.0g light yellow oil that was diluted with 65 mL ethyl acetate and washed with 2x50 mL 5 % aq. K₂CO₃, 1x10 mL brine, dried over Na₂SO₄ and concentrated in vacuo

to yield 7.5g (87%) vinyl triflate, (m/e=277(M+H))
suitable for use without further purification.

Part C: Preparation of methyl 2,2-dimethyl-3-
5 carboxyl-but-3-enoate.




10

A 250 mL Fisher Porter bottle was charged with 7.5g
15 (27 mmol) of compound prepared in Part B, 50 mL dry
DMF, 360 mg (1.37 mmol) triphenyl phosphine and 155
mg (.69 mmol) palladium (II) acetate. The reaction
mixture was purged twice with N₂ then charged with 30
psig CO. Meanwhile a solution of 20 mL dry DMF and
20 7.56 mL (54 mmol) NEt₃ was cooled to 0°C to this was
added 2.0g (43 mmol) of 99% formic acid. The
mixture was swirled and added to the vented Fisher
Porter tube. The reaction vessel was recharged to

40 psig of CO and stirred 6 hours @ room temperature. The reaction mixture was concentrated in vacuo and partitioned between 100 mL of ethyl acetate and 75 mL 5% aq. K_2CO_3 . The aqueous phase was washed with 1x40 mL additional ethyl acetate and then acidified with concentrated HCl/ice. The aqueous phase was extracted with 2x70 mL of ethyl acetate and the organics were dried and concentrated to yield 3.5g (75%) white crystals, mp 72-75°C, identified as the desired product (m/e= 173 (M+H)).


Part D: Preparation of methyl 2,2-dimethyl-3-methylsuccinate, isomer #1.



A steel hydrogenation vessel was charged with 510 mg (3.0 mmol) acrylic acid, from Part C, and 6 mg Ru

(acac)₂ (R-BINAP) in 10 ml degassed MeOH. The reaction was hydrogenated at 50 psig/room temperature for 12 hours. The reaction was then filtered through celite and concentrated to 500 mg clear oil which was shown to be a 93:7 mixture of isomer #1 and #2, respectively as determined by GC analysis using a 50 M ,B-cyclodextrin column (chiral GC): 150°C - 15 min. then ramp 2°C/min.; isomer #1, 17.85 minute retention time, isomer #2, 18-20 minute retention time.

Part E: Preparation of methyl 2,2-dimethyl-3-methylsuccinate, Isomer #2.




A steel hydrogenation vessel was charged with 500 mg (2.9 mmol) acrylic acid, Part C, and 6 mg Ru(OAc)(acac)(S-BINAP) in 10 mL degassed MeOH. The reaction was hydrogenated at 50 psig/room temperature for 10 hours. The reaction was filtered through celite and concentrated in vacuo to yield 490 mg of product as a 1:99 mixture of isomers #1 and #2, respectively, as determined by chiral GC as above.

10

Example 15: Preparation of Chiral Succinamides from Itaconic Anhydride.

Part A: Preparation of 4-N-benzyl itaconamide.

15




20

A 500 mL three necked round bottomed flask equipped with a dropping funnel, mechanical stirrer, nitrogen inlet and reflux condenser was charged with itaconic
5 anhydride (33.6g, 0.3 mol) and 150 mL of toluene. This solution was added a solution of benzylamine (32.1g, 0.3 mol) in 50 mL of toluene dropwise over 30 minutes at room temperature. The solution was stirred at this temperature an additional 3 hours
10 and then the solid product isolated by filtration on a Buchner funnel. The crude product, 64.6g, 98%, was recrystallized from 300 mL of isopropyl alcohol to give after two crops 52.1g, 79% of pure product, mp 149-150 °C.

15


Part B: Preparation of 2(R)-Methyl 4-N-benzyl succinamide.

20



A large Fisher-Porter bottle was charged with the
5 acid from the above reaction (10.9Sg, 0.05 mol),
rhodium (R,R)-DiPAMP (220mg, 0.291 mmol) and 125 mL
of degassed methanol. The solution was then
hydrogenated at 40 psig for 16 hours at room
temperature. After the hydrogen uptake ceased, the
10 vessel was opened and the solution concentrated in
vacuo to give a yellow solid, 11.05g, 100%. The
product was then taken up in absolute ethanol and
allowed to stand whereupon crystals of the desired
product formed, 7.98g, 72%, mp 127-129 °C, [α]_D @
15 25°C=+14.9° (c=1.332, EtOH), ¹H NMR (CDCl₃) 300MHz
7.30(m, 5H), 6.80(brs, 1H), 4.41(d, J=5.8Hz, 2H),
2.94(m, 1H), 2.62(dd, J=8.1, 14.9Hz, 1H), 2.33(dd,
J=5.5, 14.9Hz, 1H), 1.23(d, J=7.2Hz, 3H).

20 Part C: Preparation of 4-N(4-
methoxybenzyl)itaconamide.




5

A 500 mL three necked round bottomed flask equipped with a dropping funnel, mechanical stirrer, nitrogen inlet and reflux condenser was charged with itaconic anhydride (44.8g, 0.4 mol) and 150 ml of toluene. This solution was added a solution of 4-methoxybenzylamine (54.8g, 0.4 mol) in 50 mL of toluene dropwise over 30 minutes at room temperature. The solution was stirred at this temperature an additional 2 hours and then the solid product isolated by filtration on a Buchner funnel. The crude product was recrystallized from ethyl acetate/ethanol to give after two crops 64.8g, 65% of pure product, mp 132-134 °C, ¹H nmr (CDCl₃) 300MHz 7.09(d, J=9.1Hz, 2H), 6.90(brt, J=5.9Hz, 1H), 6.74(d, J=9.1Hz, 2H), 6.22(s, 1H), 5.69(s, 1H), 4.24(d, J=5.9Hz, 2H), 3.69(s, 3H), 3.15(s, 2H). ¹³C

nmr (CDCl₃) 170.52, 169.29, 159.24, 135.61, 131.08,
129.37, 128.97, 114.36, 55.72, 43.37, 40.58.

Part D: Preparation of 2(R)-Methyl-4-N(4-
5 methoxybenzyl)succinamide.

10



15

A large Fisher-Porter bottle was charged with the
acid from the above reaction (5.00 g, 0.02 mol),
rhodium (R,R)-DiPAMP (110 mg, 0.146 mmol) and 50 mL
20 of degassed methanol. The starting acid was not
completely soluble initially, but as the reaction
progressed the solution became homogeneous. The
solution was then hydrogenated at 40 psig for 16

hours at room temperature. After the hydrogen uptake ceased, the vessel was opened and the solution concentrated in vacuo to give a yellow solid. The crude product was then taken up in ethyl acetate and washed three times with sat. aq. NaHCO₃ solution. The combined aqueous extracts were acidified to pH=1 with 3 N HCl and then extracted three times with ethyl acetate. The combined ethyl acetate extracts were washed with brine, dried over anhyd. MgSO₄, filtered and concentrated to give the expected product as a white solid, 4.81g, 95%. This material was recrystallized from a mixture of methyl ethyl ketone/hexane to give 3.80g, 75 % of pure product, $[\alpha]_D^{25} = +11.6^\circ$ ($c=1.572$, MeOH). ¹H nmr (CDC13) 300MHz 11.9(brs, 1H), 7.18(d, J=9.2Hz, 2H), 6.82(d, J=9.2Hz, 2H), 6.68(brt, J=5.6Hz, 1H), 4.33(d, J=5.6Hz, 2H), 3.77(s, 3H), 2.92(ddq, J=7.9, 5.4, 7.3Hz, 1H), 2.60(dd, J=5.4, 15.0Hz, 1H), 2.30(dd, J=7.9, 15.0Hz, 1H), 1.22(d, J=7.3Hz, 3H).

20

Example 16: Preparation of Trans-mono-ethyl 1,2-Cyclopropanedicarboxylate.

To a solution of 4.60g (24.7 mmol) of trans-diethyl-1,2-cyclopropanedicarboxylate in 100 mL of 50:50 v:v tetrahydrofuran/water was added 1.24g (29.6 mmol) of lithium hydroxide. After 17 hours, the

5 tetrahydrofuran was removed in vacuo, the water layer washed with ethyl acetate, acidified with 1N hydrochloric acid and reextracted with ethyl acetate. The organic layer was dried and stripped to afford 2.1g of crude product. After

10 recrystallization from diethylether/hexane and then methylene chloride/hexane, one obtains 1.1g (28 %) of trans-monoethyl-1,2-cyclopropanedicarboxylate, $m/e = 159$ (M + H).

15 Example 17: Preparation of 2(R)-Methyl-4-benzyl Succinate.

Part A:

20 To a suspension of 24.7g (0.22 mol) of itaconic anhydride in 100 mL of anhydrous toluene at reflux under a nitrogen atmosphere was added dropwise over 30 minutes 23.9g (0.22 mol) of benzyl alcohol. The

insoluble material dissolved to provide a homogeneous solution which was refluxed for 1.5 hours. The solution was cooled to room temperature, then in an ice bath and the resulting white
5 precipitate collected by filtration to afford 24.8g (51%) of 4-benzyl itaconate.

Part B:

10 To a solution of 2.13g (9.5 mmol) of the product from Part A in 12 mL of methylene chloride at 0°C was added 4.02g (29.1 mmol) of para-methoxybenzyl alcohol, 605 mg (4.95 mmol) of N,N-dimethyl-4-aminopyridine, 128 mg of N,N-dimethyl-4-
15 aminopyridine hydrochloride salt and then 2.02g (4.7 mmol) dicyclohexylcarbodiimide (DCC). After stirring at 0°C for 1 hour and then room temperature for 2 hours, the precipitate was collected and discarded. The filtrate was washed with 0.5 N HCl,
20 sat. NaHCO₃, dried and stripped to afford 4.76g of crude product. This was chromatographed on silica gel using 0-50% ethyl acetate/hexane to afford 1.24g of pure 4'-methoxybenzyl-4-benzylitaconate.

Part C:

A solution of 1.24g (3.65 mmol) of product from Part
5 B and 20 mg of [(R,R)-DiPAMP)cyclooctadienylrhodium]
tetrafluoroborate in 30 mL of methanol was
thoroughly degassed, flushed with nitrogen and then
hydrogen and then stirred under 50 psig of hydrogen
for 15 hours. The solution was filtered and
10 stripped, dissolved in methylene chloride and washed
with sat. NaHCO₃, dried and stripped to afford 0.99g
of a brown oil. This was then dissolved in 40 mL of
methylene chloride, 3 mL of trifluoroacetic acid
added and the solution stirred at room temperature
15 for 3.5 hours. Water was added and separated and
the organic layer extracted with sat. NaHCO₃. The
aqueous layer was acidified and reextracted with
ethyl acetate, separated and the organic layer
washed with brine, dried and stripped to afford 320
20 mg (50%) of 2(R)-methyl-4-benzylsuccinic acid.

Example 18: Preparation of 2(S)-Methyl-4-benzyl
Succinate.

000220"495363
A solution of 1.41g (4.1 mmol) of 4'-methoxybenzyl-
4-benzylitaconate and 25 mg of [(S,S-
DiPAMP)cyclooctadienyl-rhodium]tetrafluoroborate in
5 20 mL of methanol was thoroughly degassed, flushed
with nitrogen and then hydrogen and then stirred
under 40 psig hydrogen for 72 hours. The solution
was filtered and concentrated to provide 1.34g of a
brown oil. This was dissolved in 40 mL of methylene
10 chloride and 3 mL of trifluoroacetic acid was added.
After stirring for 4 hours, water was added,
separated and the organic layer extracted with sat.
NaHCO₃. The aqueous layer was separated,
reacidified, extracted with ethyl acetate which was
15 separated, washed with brine, dried and stripped to
afford 440 mg of 2(S)-methyl-4-benzylsuccinic acid
(also known as, 2(S)-Methyl-4-benzyl succinate).

Example 19: Preparation of 3(R)-Methyl-4-benzyl
20 Succinate.

Part A:

In a similar manner to the procedure used above in Example 17, Part A, p-methoxybenzyl alcohol was reacted with itaconic anhydride in refluxing toluene to provide 4-(p-methoxybenzyl)itaconate.

5

Part B:

To a solution of 3.30g (13.2 mmol) of the product from Part A in 17 mL of toluene, was added 2.08g (13.7 mmol) of 1,8 diazabicyclo[5.4.0]undec-7-ene
10 and then 2.35g (13.7 mmol) of benzyl bromide. After 2 hours, the solution was filtered and the filtrate washed with sat. NaHCO₃, 3N HCl, brine, dried and concentrated to afford 3.12g of an oil. After chromatography on silica gel using 0-5 % ethyl
15 acetate/hexane one obtains 2.19g (49 %) of benzyl 4-(4-methoxybenzyl) itaconate.

Part C:


A solution of 1.22g (3.6 mmol) of product from Part
20 B and 150 mg of [((R,R-DiPAMP)) cyclooctadienylrhodium] tetrafluoroborate in 15 mL of methanol was thoroughly degassed, flushed with nitrogen and then hydrogen and hydrogenated under 50

psig for 16 hours. The solution was filtered and concentrated to afford 1.2g of a brown oil. This was dissolved in 5 mL of methylene chloride and 5 mL of toluene and 3 mL of trifluoroacetic acid was added. After 4 hours, the solvents were removed in vacuo, the residue dissolved in methylene chloride, which was then extracted with sat. NaHCO₃. After separation, the aqueous layer was acidified, reextracted with methylene chloride which was then dried and concentrated to afford 470 mg (60%) of 3(R)-methyl-4-benzylsuccinic acid (also known as, 3(R)-methyl-4-benzyl succinate).

Example 20: Preparation of 3(S)-Methyl-4-benzyl Succinate.

This was prepared in an identical manner to the previous example (Example 19) except that the asymmetric hydrogenation step was done in the presence of [((S,S-DiPAMP)cyclooctadienyl)rhodium]-tetrafluoroborate as catalyst.

Example 21:




10

The compound of this example is prepared using methods illustrated and referred to hereinabove.

15


Example 22:



The compound of this example is prepared using
5 methods illustrated and referred to hereinabove.

Example 23:

10




15

20 The compound of this example is prepared using
methods illustrated and referred to hereinabove.

Example 24

5

10




15

The compound of this example is prepared using methods illustrated and referred to hereinabove.

Example 25:

20




5

The compound of this example is prepared using
methods illustrated and referred to hereinabove.

10

Example 26:

15




20

The compound of this example is prepared using methods illustrated and referred to hereinabove.

Example 27:

5


10



15 The compound of this example is prepared using methods illustrated and referred to hereinabove.

Example 28:

20




5

The compound of this example is prepared using methods illustrated and referred to hereinabove.

Example 29:

10


15



20

The compound of this example is prepared using methods illustrated and referred to hereinabove.


Example 30:



5

The compound of this example is prepared using methods illustrated and referred to hereinabove.

10 Example 31:




20

The compound of this example is prepared using methods illustrated and referred to hereinabove.

Example 32:

5



10

The compound of this example is prepared using methods illustrated and referred to hereinabove.

Example 33: Assays

15

Part A: Enzyme Assay

Utilizing an enzyme assay as described below, the compounds set forth in Examples 4, 6, 10, 12 and 12C inhibited the HIV enzyme in an amount ranging from about 3 to about 100% inhibition at a concentration of 10 microMolar. The calculated IC₅₀ (inhibiting concentration 50%, i.e., the concentrations at which the inhibitor compound reduces enzyme activity by

50%) values are shown in Table 1. The enzyme method is described below. The substrate is 2-aminobenzoyl-Ile-Nle-Phe(p-NO₂)-Gln-ArgNH₂. The positive control is MVT-101 (Miller, M. et al, Science, 246, 1149 (1989)) The assay conditions are as follows:

Assay buffer: 20 mM sodium phosphate, pH 6.4

10 20% glycerol

1 mM EDTA

1 mM DTT

0.1% CHAPS

15 The above described substrate is dissolved in DMSO, then diluted 10 fold in assay buffer. Final substrate concentration in the assay is 80 μ M.

HIV protease is diluted in the assay buffer to a
20 final enzyme concentration of 12.3 nanomolar, based on a molecular weight of 10,780.

The final concentration of DMSO is 14% and the final concentration of glycerol is 18%. The test compound

is dissolved in DMSO and diluted in DMSO to 10x the test concentration; 10µL of the enzyme preparation is added, the materials mixed and then the mixture is incubated at ambient temperature for 15 minutes.

- 5 The enzyme reaction is initiated by the addition of 40 µL of substrate. The increase in fluorescence is monitored at 4 time points (0, 8, 16 and 24 minutes) at ambient temperature. Each assay is carried out in duplicate wells.

10

Part B: CEM Cell Assay

- The effectiveness of the compounds tested in Part A was also determined in a CEM cell assay. The HIV
- 15 inhibition assay method of acutely infected cells is an automated tetrazolium based colorimetric assay essentially that reported by Pawles et al, J. Virol. Methods 20, 309-321 (1988). Assays were performed in 96-well tissue culture plates. CEM
- 20 cells, a CD4⁺ cell line, were grown in RPMI-1640 medium (Gibco) supplemented with a 10% fetal calf serum and were then treated with polybrene (2pg/mL). An 80 µL volume of medium containing 1×10^4 cells was dispensed into each well of the tissue culture

plate. To each well was added a 100 μ L volume of
test compound dissolved in tissue culture medium (or
medium without test compound as a control) to
achieve the desired final concentration and the
5 cells were incubated at 37°C for 1 hour. A frozen
culture of HIV-1 was diluted in culture medium to a
concentration of 5×10^4 TCID₅₀ per mL (TCID₅₀ = the
dose of virus that infects 50% of cells in tissue
culture), and a 20 μ L volume of the virus sample
10 (containing 1000 TCID₅₀ of virus) was added to wells
containing test compound and to wells containing
only medium (infected control cells). Several wells
received culture medium without virus (uninfected
control cells). Likewise, the intrinsic toxicity of
15 the test compound was determined by adding medium
without virus to several wells containing test
compound. In summary, the tissue culture plates
contained the following experiments:

	Cells	Drug	Virus
1.	+	-	-
2.	+	+	-
3.	+	-	+
5 4.	+	+	+

In experiments 2 and 4, the final concentrations of test compounds were 1, 10, 100 and 500 µg/mL.

10 Either azidothymidine (AZT) or dideoxyinosine (ddI) was included as a positive drug control. Test compounds were dissolved in DMSO and diluted into tissue culture medium so that the final DMSO concentration did not exceed 1.5% in any case. DMSO

15 was added to all control wells at an appropriate concentration.

Following the addition of virus, cells were incubated at 37°C in a humidified, 5% CO₂ atmosphere

20 for 7 days. Test compounds could be added on days 0, 2 and 5 if desired. On day 7, post-infection, the cells in each well were resuspended and a 100µL sample of each cell suspension was removed for assay. A 20µL volume of a 5 mg/mL solution of 3-

(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) was added to each 100 μ L cell
suspension, and the cells were incubated for 4 hours
at 27°C in a 5% CO₂ environment. During this
5 incubation, MTT is metabolically reduced by living
cells resulting in the production in the cell of a
colored formazan product. To each sample was added
100 μ L of 10% sodium dodecylsulfate in 0.01 N HCl to
lyse the cells, and samples were incubated
10 overnight. The absorbance at 590 nm was determined
for each sample using a Molecular Devices microplate
reader. Absorbance values for each set of wells is
compared to assess viral control infection,
uninfected control cell response as well as test
15 compound by cytotoxicity and antiviral efficacy.

The calculated EC₅₀ (effective concentration 50%,
i.e., the concentration at which the inhibitor
compound reduces cytopathicity by 50%) and TD₅₀
20 (toxic dose 50%, i.e., the concentration at which
the inhibitor compound reduces cellular viability by
50%) values for these compounds are also shown in
Table 1.

Table 1






Structure	Enzyme Inhibition (IC ₅₀)	Antiviral Activity in Cell Culture (EC ₅₀)	Cell Toxicity (TD ₅₀)
	7nM	42nM	58,000nM
	2nM	52nM	2,000nM
	9nM	37nM	5,000nM

Table 1

Structure	Enzyme Inhibition (IC ₅₀)	Antiviral Activity in Cell Culture (EC ₅₀)	Cell Toxicity (TD ₅₀)
	9nM	98nM	59,000nM
	23nM	184nM	50,000nM

It is expected that compounds of Formulae I-IV would
 5 be active when tested in the assays described in
 Example 33 above.

The compounds of the present invention can be used
 in the form of salts derived from inorganic or

organic acids. These salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate and undecanoate.

Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.

Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.

Total daily dose administered to a host in single or divided doses may be in amounts, for example, from 0.001 to 10 mg/kg body weight daily and more usually 0.01 to 1 mg. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

The dosage regimen to give relief from or ameliorate a disease condition (i.e., treatment) or protecting against the further spreading of the infection (i.e., prophylaxis) with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized and whether the compound is administered as part of a drug combination.

Thus, the dosage regimen actually employed may vary widely and therefore deviate from the preferred dosage regimen set forth above.

The compounds of the present invention may be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration may

THEORY

THEORY

THEORY

- Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and
- 5 polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
- 10 Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose lactose or starch. Such
- 15 dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering
- 20 agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions,

solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and
5 suspending agents, and sweetening, flavoring, and perfuming agents.

Pharmaceutically acceptable carriers encompass all the foregoing and the like.

10

While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more immunomodulators, antiviral agents or other
15 antiinfective agents. For example, the compounds of the invention can be administered in combination with AZT, other nucleoside antivirals, other HIV-protease inhibitors or with iminosugars such as N-butyl-1-deoxynojirimycin for the prophylaxis and/or
20 treatment of AIDS or HIV infection. The additional antiviral agents can be selected, if desired, using phenotyping and/or genotyping methods to determine sensitivity/resistance parameters that can be used by the skilled person as an aid in the selection of

the drug or drugs to be used in combination.

Included in the possibilities of for combination therapy are drugs useful for the treatment of the secondary symptoms of HIV infection, ARC or AIDS.

- 5 When administered as a combination, the therapeutic agents can be formulated as separate compositions which are given at the same time or different times, or the therapeutic agents can be given as a single composition.

10

- The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are
15 intended to be within the scope and nature of the invention which are defined in the appended claims.


- The preceding examples can be repeated with similar success by substituting the generically or
20 specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can
5 make various changes and modifications of the invention to adapt it to various usages and conditions.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223

What is Claimed is:

1. A compound represented by the formula:



(Formula I)

- or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein:

R represents hydrogen, alkoxycarbonyl, aryloxy carbonylalkyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxy carbanoyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocycloxy carbonyl, heteroaralkoxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroarylcarbonyl, heteroaryloxy carbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aralkylaminoalkylcarbonyl, aminoalkanoyl, aminocarbonyl, aminocarbonylalkyl, alkylaminoalkylcarbonyl, and mono- and disubstituted

aminocarbonyl and aminoalkanoyl radicals wherein the substituents are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, alkoxy carbonyl, arylalkyloxycarbonyl, and heterocycloalkylalkyl radicals, or in the case of disubstituted aminoalkanoyl, said substituents along with the nitrogen atom to which they are attached form a heterocyclyl or heteroaryl radical;

R' represents radicals defined for R³, or R and R' together with the nitrogen to which they are attached form a heterocycloalkyl or heteroaryl radical;

R¹ represents hydrogen, -CH₂SO₂NH₂, -CO₂CH₃, -CH₂CO₂CH₃, -C(=O)NH₂, -C(=O)NHCH₃, -C(=O)N(CH₃)₂, -CH₂C(=O)NHCH₃, -CH₂C(=O)N(CH₃)₂, alkyl, thiolalkyl and the corresponding sulfoxide and sulfone derivatives thereof, alkenyl, haloalkyl, alkoxyalkyl, alkynyl and cycloalkyl radicals and amino acid side chains selected from the group consisting of asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, leucine, isoleucine, allo-isoleucine, tert-leucine, alanine, phenylalanine, ornithine, histidine, norleucine, glutamine, valine, threonine, allo-threonine, serine, aspartic acid and beta-cyano alanine, side chains;

R² represents alkylthioalkyl, cycloalkylthioalkyl or arylthioalkyl radicals, which radicals are optionally substituted with a substituent selected from the group

consisting of $-\text{NO}_2$, $-\text{OR}^{15}$, $-\text{SR}^{15}$, and halogen radicals,
wherein R^{15} represents hydrogen and alkyl radicals;

5 R^3 represents hydrogen, alkyl, alkenyl, alkynyl,
haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl,
cycloalkylalkyl, heterocycloalkyl, heteroaryl,
heterocycloalkylalkyl, aryl, aralkyl, and
heteroaralkyl radicals;


10 Y' represents O, S and NR^3 ;

R^4 and R^5 together with the nitrogen atom to which they
are bonded represent a N-heterocyclic moiety; and R^6
represents hydrogen and alkyl radicals.


15

2. A compound of Claim 1 where R^4 and R^5 together with
the nitrogen atom to which they are bonded represent a
N-heterocyclic moiety containing 5, 6 or 7 members
when monocyclic, 5, 6 or 7 members in a ring with 1, 2
20 or 3 members in a bridge when a bridged monocyclic,
11, 12 or 13 members when bicyclic, and 11 to 16
members when tricyclic.


3. A compound of Claim 2 where R^4 and R^5 together with
25 the nitrogen atom to which they are bonded form a N-
heterocyclic moiety selected from the group consisting
of formulae (A) through and including
(J)




(A)




(B)




(C)




(D)




(E)




(F)



(G)




(H)



(J)

5 wherein:

R⁹ represents hydrogen, alkyl, alkoxycarbonyl, monoalkylcarbamoyl, monoaralkylcarbamoyl, monoarylcarbamoyl or a group of the formula:



R¹⁰ and R¹¹ each represents alkyl;

R¹² represents hydrogen, hydroxy, alkoxycarbonylamino or acylamino;

R¹³ represents hydrogen, alkyl, aryl, alkoxycarbonyl or acyl;

m is 1, 2, 3, or 4;

p is 1 or 2;

q is 0, 1 or 2; and R⁶ represents hydrogen and alkyl radicals.

4. A compound of Claim 1 where Y' is oxygen.

5. A compound of Claim 1 where R² is arylthioalkyl.

6. A compound of Claim 2 where R⁴ and R⁵ together with the nitrogen atom to which they are bonded represent a bicyclic N-heterocyclic moiety.

5

7. A compound of Claim 1 where R is hydrogen, alkoxycarbonyl, arylalkylcarbonyl, heterocyclecarbonyl, aminoalkanoyl, mono-substituted aminoalkanoyl, di-substituted aminoalkanoyl.

10


8. A compound of Claim 1 where R' is hydrogen.

9. A compound of Claim 3 where R¹ is hydrogen, alkyl, thioalkyl, alkylthioalkyl, alkenyl, alkynyl and cycloalkyl.

15

10. A compound of Claim 1 represented by the formula


20



25

wherein R, R', R¹, R⁶, Y', R⁴ and R⁵ are as described herein.

11. A compound of Claim 3 represented by the formula



wherein R, R', R¹, R⁶ and Y' are as described herein.

12. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutical carrier.

13. A pharmaceutical composition comprising a compound of Claim 1 and pharmaceutical carriers.


14. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a compound of Claim 1.

15. Method of treating a retroviral infection comprising administering a pharmaceutical composition of a compound of Claim 1.

16. Method of treating HIV infection comprising administering a pharmaceutical composition of a compound of Claim 1.

[illegible][illegible]

19. A compound represented by the formula:



(Formula II)

or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein:

R' represents radicals defined for R³;

t represents either 0 or 1;

R¹ represents hydrogen, -CH₂SO₂NH₂, -CO₂CH₃, -CH₂CO₂CH₃, -C(O)NH₂, -C(O)NHCH₃, -C(O)N(CH₃)₂, -CH₂C(O)NHCH₃, -CH₂C(O)N(CH₃)₂, alkyl, alkylthioalkyl, thioalkyl and the corresponding sulfoxide and sulfone derivatives thereof, alkenyl, alkynyl, alkoxyalkyl, haloalkyl and cycloalkyl radicals and amino acid side chains selected from the group consisting of asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, leucine, isoleucine, allo-isoleucine, tert-leucine, alanine, phenylalanine, ornithine, histidine, norleucine,

glutamine, valine, threonine, allo-threonine, serine, aspartic acid and beta-cyano alanine side chains;

5 R^2 represents alkylthioalkyl, cycloalkylthioalkyl or arylthioalkyl radicals, which radicals are optionally substituted with a substituent selected from the group consisting of $-NO_2$, $-OR^{15}$, $-SR^{15}$, and halogen radicals, wherein R^{15} represents hydrogen and alkyl radicals;

10 R^3 represents hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, and heteroaralkyl radicals;

15 Y' represents O, S and NR^3 ;

R^4 and R^5 together with the nitrogen atom to which they are bonded represent a N-heterocycle;


20 R^6 represents hydrogen and alkyl radicals;

and R^{20} and R^{21} represent radicals as defined for R^1 .


25 20. A compound of Claim 19 where R^4 and R^5 together with the nitrogen atom to which they are bonded represent a N-heterocyclic moiety containing 5, 6 or 7 members when monocyclic, 5, 6 or 7 members in a ring with 1, 2 or 3 members in a bridge when a bridged
30 monocyclic, 11, 12 or 13 members when bicyclic, and 11

2025


2025




(A)




(B)




(C)




(D)




(E)




(F)



(G)



(H)




(J)

5 wherein:

R⁹ represents hydrogen, alkyl, alkoxy carbonyl, monoalkylcarbamoyl, monoaralkylcarbamoyl, monoarylcarbamoyl or a group of the formula:

5



10

R¹⁰ and R¹¹ each represents alkyl;

15 R¹² represents hydrogen, hydroxy, alkoxy carbonylamino or acylamino;

R¹³ represents hydrogen, alkyl, aryl, alkoxy carbonyl or acyl;

20

m is 1, 2, 3, or 4;

p is 1 or 2;

25 q is 0, 1 or 2; and R⁵ represents hydrogen and alkyl radicals.

30

22. A compound of Claim 19 where Y' is oxygen.

23. A compound of Claim 19 where R² is arylthioalkyl.

24. A compound of Claim 19 where t is 0.

25. A compound of Claim 20 where R⁴ and R⁵ together
5 with the nitrogen atom to which they are bonded
represent a bicyclic N-heterocyclic moiety.

26. A compound of Claim 19 where R²⁰ and R²¹ are
hydrogen or alkyl.

10


27. A compound of Claim 19 where R' is alkyl, aryl or
arylalkyl.

15

28. A compound of Claim 19 where R¹ is hydrogen,
alkyl, thioalkyl, alkylthioalkyl, alkenyl, alkynyl and
cycloalkyl.

29. A compound of Claim 19 represented by the Formula


20



25

wherein R', R¹, R⁶, R⁴, R⁵, R²⁰, R²¹, Y' and t are as
described herein.

30. A compound of Claim 21 represented by the formula



31. A pharmaceutical composition comprising a compound of Claim 19 and a pharmaceutical carrier.

32. A pharmaceutical composition comprising a compound of Claim 19 and pharmaceutical carriers.

33. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a compound of Claim 19.


34. Method of treating a retroviral infection comprising administering a pharmaceutical composition of a compound of Claim 19.

35. Method of treating HIV infection comprising administering a pharmaceutical composition of a compound of Claim 19.

36. Method of treating AIDS comprising administering a pharmaceutical composition of a compound of Claim 19.
37. Method of treating AIDS comprising
- 5 administering a pharmaceutical composition of a compound of Claim 19 in combination with other drugs for the treatment of AIDS or the symptoms of AIDS.

2025-04-15 14:53:50

38. A compound represented by the formula:



(Formula III)

or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein:

t represents either 0 or 1;

Rⁱ represents hydrogen, -CH₂SO₂NH₂, -CO₂CH₃, -CH₂CO₂CH₃, -C(O)NH₂, -C(O)NHCH₃, -C(O)N(CH₃)₂, -CH₂C(O)NHCH₃, -CH₂C(O)N(CH₃)₂, alkyl, thioalkyl, thioalkyl and the corresponding sulfoxide and sulfone derivatives thereof, alkenyl, alkynyl, alkoxyalkyl, haloalkyl and cycloalkyl radicals and amino acid side chains selected from the group consisting of asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, leucine, isoleucine, allo-isoleucine, tert-leucine, alanine,

phenylalanine, ornithine, histidine, norleucine, glutamine, valine, threonine, allo-threonine, serine, aspartic acid and beta-cyano alanine side chains;

- 5 R^2 represents alkylthioalkyl, cycloalkylthioalkyl, or arylthioalkyl radicals, which radicals are optionally substituted with a substituent selected from the group consisting of $-NO_2$, $-OR^{15}$, $-SR^{15}$, and halogen radicals, wherein R^{15} represents hydrogen and alkyl radicals;

10

R^3 represents hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, and

15

heteroaralkyl radicals;

X' represent O, N and $C(R^{17})$ where R^{17} represents hydrogen and alkyl radicals;

20

Y' and Y'' independently represent O, S and NR^3 ;

R^4 and R^5 together with the nitrogen atom to which they are bonded represent a N-heterocycle;

25

R^6 represents hydrogen and alkyl radicals;

R^{10} , R^{11} and R^{12} independently represent radicals as defined for R^1 , or one of R^1 and R^{10} together with one of R^{11} and R^{12} and the carbon atoms to which they are attached form a cycloalkyl radical; and

30

R³³ and R³⁴ independently represent radicals as defined for R³, or R³³ and R³⁴ together with X' represent cycloalkyl, aryl, heterocyclyl and heteroaryl radicals, provided that when X' is O, R³⁴ is absent.


5

39. A compound of Claim 38 where R⁴ and R⁵ together with the nitrogen atom to which they are bonded represent a N-heterocyclic moiety containing 5, 6 or 7 members when monocyclic, 5, 6 or 7 members in a ring with 1, 2 or 3 members in a bridge when a bridged monocyclic, 11, 12 or 13 members when bicyclic, and 11 to 16 members when tricyclic; and R⁶ represents hydrogen and alkyl radicals.


10

15


40. A compound of Claim 39 where R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a N-heterocyclic moiety selected from the group consisting of formulae (A) through and including (J)




(A)




(B)




(C)




(D)




(E)




(F)



(G)



(H)




(J)

5 wherein:

R⁹ represents hydrogen, alkyl, alkoxycarbonyl, monoalkylcarbamoyl, monoaralkylcarbamoyl, monoarylcarbamoyl or a group of the formula:

5



10

R¹⁰ and R¹¹ each represents alkyl;

15 R¹² represents hydrogen, hydroxy, alkoxycarbonylamino or acylamino;

R¹³ represents hydrogen, alkyl, aryl, alkoxycarbonyl or acyl;

20

m is 1, 2, 3, or 4;

p is 1 or 2;

25 q is 0, 1 or 2; and R⁶ represents hydrogen and alkyl radicals.

41. A compound of Claim 38 where Y' and Y" are
30 oxygen.

42. A compound of Claim 38 where R^2 is arylthioalkyl.

43. A compound of Claim 38 where t is 0.

5 44. A compound of Claim 39 where R^4 and R^5 together with the nitrogen atom to which they are bonded represent a bicyclic N-heterocyclic moiety.

45. A compound of Claim 38 where X' is oxygen.

10

46. A compound of Claim 38 where X' is nitrogen.

47. A compound of Claim 38 where R^{33} and R^{34} are hydrogen, alkyl, cycloalkyl, aralkyl or haloalkyl.

15

48. A compound of Claim 38 where R^{33} and R^{34} taken together with the nitrogen to which they are attached form a heterocyclic ring.


20

49. A compound of Claim 40 where R^1 is hydrogen, alkyl, thioalkyl, alkylthioalkyl, alkenyl, alkynyl and cycloalkyl.

25


50. A compound of Claim 38 where R^1 , R^{10} , R^{31} , R^{32} are hydrogen or alkyl.

51. A compound of Claim 38 represented by the Formula



10 wherein R^1 , R^6 , Y' , Y'' , R^4 , R^5 , R^{30} , R^{31} , R^{32} , R^{33} , R^{34} and t are as described herein.

52. A compound of Claim 40 represented by the formula



wherein R , R' , R^1 , R^6 and Y' are as described herein.

53. A pharmaceutical composition comprising a
25 compound of Claim 38 and a pharmaceutical carrier.

54. A pharmaceutical composition comprising a
compound of Claim 38 and a pharmaceutical carriers.

55. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a compound of Claim 38.

56. Method of treating a retroviral infection
5 comprising administering a pharmaceutical composition of a compound of Claim 38.


57. Method of treating HIV infection comprising administering a pharmaceutical composition of a
10 compound of Claim 38.

58. Method of treating AIDS comprising administering a pharmaceutical composition of a compound of Claim 38.

15 59. Method of treating AIDS comprising administering a pharmaceutical composition of a compound of Claim 38 in combination with other drugs for the treatment of AIDS or the symptoms of AIDS.

009329 435350

60. A compound represented by the formula:



(Formula IV)

or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein:

R represents hydrogen, alkoxycarbonyl, aryloxy carbonylalkyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxy carbanoyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocycloxy carbonyl, heteroaralkoxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroarylcarbonyl, heteroaryloxy carbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aralkylaminoalkylcarbonyl, aminoalkanoyl,

aminocarbonyl, aminocarbonylalkyl,
alkylaminoalkylcarbonyl, and mono- and disubstituted
aminocarbonyl and aminoalkanoyl radicals wherein the
substituents are selected from the group consisting of
5 alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroaralkyl, heterocycloalkyl, and
heterocycloalkylalkyl radicals, or in the case of
disubstituted aminoalkanoyl, said substituents along
with the nitrogen atom to which they are attached form
10 a heterocyclyl or heteroaryl radical;

R' represents radicals defined for R¹, or R and R'
together with the nitrogen to which they are attached
form a heterocycloalkyl or heteroaryl radical;

15 n represents 1 or 2;

R¹ represents hydrogen, -CH₂SO₂NH₂, -CO₂CH₃, -CH₂CO₂CH₃, -
C(0)NH₂, -C(0)NHCH₃, -C(0)N(CH₃)₂, -CH₂C(0)NHCH₃, -
20 CH₂C(0)N(CH₃)₂, alkyl, thioalkyl and the corresponding
sulfoxide and sulfone derivatives thereof, alkenyl,
alkynyl, haloalkyl, alkoxyalkyl and cycloalkyl radicals
and amino acid side chains selected from the group
consisting of asparagine, S-methyl cysteine and the
25 corresponding sulfoxide and sulfone derivatives
thereof, glycine, leucine, isoleucine, allo-isoleucine,
tert-leucine, alanine, phenylalanine, ornithine,
histidine, norleucine, glutamine, valine, threonine,
allo-threonine, serine, aspartic acid and beta-cyano
30 alanine side chains;

R^{1'} and R^{1''} independently represent hydrogen and radicals as defined for R³;

5 R² represents alkylthioalkyl, cycloalkylthioalkyl, or arylthioalkyl radicals, which radicals are optionally substituted with a substituent selected from the group consisting of -NO₂, -OR¹⁵, -SR¹⁵, and halogen radicals, wherein R¹⁵ represents hydrogen and alkyl radicals;

10 R³ represents hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, and heteroaralkyl radicals;


15 Y' represents O, S and NR³;

R⁴ and R⁵ together with the nitrogen atom to which they are bonded represent a N-heterocyclic moiety;


20 R⁶ represents hydrogen and alkyl radicals.

61. A compound of Claim 60 where R⁴ and R⁵ together with the nitrogen atom to which they are bonded
25 represent a N-heterocyclic moiety containing 5, 6 or 7 members when monocyclic, 5, 6 or 7 members in a ring with 1, 2 or 3 members in a bridge when a bridged monocyclic, 11, 12 or 13 members when bicyclic, and 11 to 16 members when tricyclic.


30




(A)




(B)




(C)




(D)




(E)




(F)



(G)



(H)




(J)

5 wherein:

R^9 represents hydrogen, alkyl, alkoxy carbonyl, monoalkylcarbamoyl, monoaralkylcarbamoyl, monoarylcarbamoyl or a group of the formula:

5



10

R^{10} and R^{11} each represents alkyl;

15 R^{12} represents hydrogen, hydroxy, alkoxy carbonylamino or acylamino;

R^{13} represents hydrogen, alkyl, aryl, alkoxy carbonyl or acyl;

20

m is 1, 2, 3, or 4;

p is 1 or 2;

25 q is 0, 1 or 2; and R^5 represents hydrogen and alkyl radicals.

64. A compound of Claim 60 where Y' is oxygen.

30

65. A compound of Claim 60 where R^2 is arylthioalkyl.

66. A compound of Claim 61 where R^4 and R^5 together with the nitrogen atom to which they are bonded represent a bicyclic N-heterocyclic moiety.

5

67. A compound of Claim 60 where R is hydrogen, alkoxycarbonyl, arylalkylcarbonyl, heterocyclecarbonyl, aminoalkanoyl, mono-substituted aminoalkanoyl, di-substituted aminoalkanoyl.

10

68. A compound of Claim 62 where $R^{1'}$ and $R^{1''}$ are hydrogen.


69. A compound of Claim 60 where R' is hydrogen.

15

70. A compound of Claim 60 where R^1 is hydrogen, alkyl, thioalkyl, alkylthioalkyl, alkenyl, alkynyl and cycloalkyl.


20 71. A compound of Claim 60 represented by the formula

25



wherein R, R' , R^1 , $R^{1'}$, $R^{1''}$, R^6 , R^4 , R^5 and Y' are as described herein.

72. A compound of Claim 63 represented by the formula



wherein R, R', R¹, R^{1'}, R^{1''}, R⁶ and Y' are as described herein.

73. A pharmaceutical composition comprising a compound of Claim 60 and a pharmaceutical carrier.

74. A pharmaceutical composition comprising a compound of Claim 60 and pharmaceutical carriers.

75. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a compound of Claim 60.

76. Method of treating a retroviral infection comprising administering a pharmaceutical composition of a compound of Claim 60.


5 77. Method of treating HIV infection comprising administering a pharmaceutical composition of a compound of Claim 60.

78. Method of treating AIDS comprising administering a pharmaceutical composition of a compound of Claim 60.

10

79. Method of treating AIDS comprising administering a pharmaceutical composition of a compound of Claim 60 in combination with other drugs for the treatment of AIDS or the symptoms of AIDS.

80. A compound represented by the formula:




(Formula IIa)

10
or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein:


15
t represents either 0 or 1;

R¹ represents hydrogen, -CH₂SO₂NH₂, -CO₂CH₃, -CH₂CO₂CH₃, -C(=O)NH₂, -C(=O)NHCH₃, -C(=O)N(CH₃)₂, -CH₂C(=O)NHCH₃, -CH₂C(=O)N(CH₃)₂, alkyl, alkylthioalkyl, thioalkyl and the corresponding sulfoxide and sulfone derivatives thereof, alkenyl, alkynyl and cycloalkyl radicals and amino acid side chains selected from the group consisting of asparagine, S-methyl cysteine and the corresponding sulfoxide and sulfone derivatives thereof, glycine, leucine, isoleucine, allo-isoleucine, tert-leucine, alanine, phenylalanine, ornithine, histidine, norleucine, glutamine, valine, threonine, allo-threonine, serine, aspartic acid and beta-cyano alanine side chains;


20
25
30




(A)




(B)




(C)




(D)




(E)




(F)



(G)




(H)



(J)

R⁹ represents hydrogen, alkyl, alkoxycarbonyl, monoalkylcarbamoyl, monoaralkylcarbamoyl, monoarylcarbamoyl or a group of the formula:



R¹⁰ and R¹¹ each represents alkyl;

R¹² represents hydrogen, hydroxy, alkoxycarbonylamino or acylamino;

R¹³ represents hydrogen, alkyl, aryl, alkoxycarbonyl or acyl;

m is 1, 2, 3, or 4;

p is 1 or 2;

q is 0, 1 or 2; and R⁶ represents hydrogen and alkyl radicals.

83. A compound of Claim 80 where Y' is oxygen.

84. A compound of Claim 80 where R² is arylthioalkyl.

85. A compound of Claim 80 where t is 0.

86. A compound of Claim 81 where R⁴ and R⁵ together
5 with the nitrogen atom to which they are bonded
represent a bicyclic N-heterocyclic moiety.

87. A compound of Claim 80 where R³³ and R³⁴ are
10 hydrogen, alkyl, cycloalkyl, aralkyl or haloalkyl.


88. A compound of Claim 80 where R³³ and R³⁴ taken
together with the nitrogen to which they are attached
form a heterocyclic ring.

89. A compound of Claim 80 where R¹ is hydrogen,
15 alkyl, thioalkyl, alkylthioalkyl, alkenyl, alkynyl and
cycloalkyl.

90. A compound of Claim 80 where R²⁰ and R²¹ are
20 hydrogen or alkyl.


91. A compound of Claim 80 represented by the Formula

25



wherein R^1 , R^6 , R^4 , R^5 , R^{20} , R^{21} , R^{33} , R^{34} , t and Y' are as described herein.

92. A compound of Claim 82 represented by the formula



15 wherein R^1 , R^6 , R^{20} , R^{21} , R^{33} , R^{34} , t and Y' are as described herein.

93. A pharmaceutical composition comprising a compound of Claim 80 and a pharmaceutical carrier.

20

94. A pharmaceutical composition comprising a compound of Claim 80 and a pharmaceutical carriers.

95. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a compound of Claim 80.


25

96. Method of treating a retroviral infection comprising administering a pharmaceutical composition of a compound of Claim 80.
- 5 97. Method of treating HIV infection comprising administering a pharmaceutical composition of a compound of Claim 80.
98. Method of treating AIDS comprising administering a
10 pharmaceutical composition of a compound of Claim 80.
99. Method of treating AIDS comprising administering a pharmaceutical composition of a compound of Claim 80 in combination with other drugs
15 for the treatment of AIDS or the symptoms of AIDS.

Abstract

HIV protease inhibitors are disclosed which are
5 characterized as having both hydroxyethylamine and
N-heterocyclic moieties.

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



SCANNED
Q1

Application deficiencies were found during scanning:

☐ Page(s) _____ of Declaration were not present:
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present:
for scanning. (Document title)

☐ Scanned copy is best available.